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INTRODUCTION 
Sporadic miscarriage is the most common pregnancy complication affecting up 
to 15% of all clinically recognized pregnancies (Stirrat 1990). Up to 3% of 
fertile couples have been diagnosed with recurrent miscarriage disease (RM) 
defined by three or more consecutive early pregnancy losses before gestational 
week 22. RM is a multifactorial disease accompanied by increased probability 
of other pregnancy complications such as preterm birth or small for gestational 
age newborns (Jivraj et al. 2001; van Oppenraaij et al. 2009). Although a 
spectrum of causes is known for RM, etiology behind approximately half of the 
cases remains unsolved and is defined as idiopathic (reviewed in (Christiansen 
et al. 2008)).  
The genetic component in the etiology of idiopathic RM has been 
acknowledged and extensively addressed by numerous studies targeting almost 
100 candidate genes to date (Kolte et al. 2011; Rull et al. 2012). However, no 
prevalent gene variants specific to the disease have been described sufficiently 
explaining the heritability of RM. Few hypothesis-free ‘omics’ studies, 
including genome-wide approach or transcriptomics of endometrial and 
placental samples (Lee et al. 2007; Li et al. 2010; Rull et al. 2013), have been 
reported identifying novel candidate genes that modify the risk of having RM 
and highlighting the potential of ‘omics’ research as the source of novel genetic 
biomarkers.  
Human chorionic gonadotropin (hCG), also termed as the ‘pregnancy 
hormone’, is essential for pregnancy establishment and maintenance. The genes 
encoding the β-subunit of the heterodimeric hCG are attractive candidates in 
studying early pregnancy success as the aberrant expression has previously been 
implicated in various pregnancy disorders, including RM (Rull and Laan 2005). 
The four highly similar genes encoding hCGβ (CGB) are co-located in the 
LHB/CGB gene cluster on chromosome 19. The complex nature of the 
LHB/CGB region has hindered the fine-scale analysis of the polymorphisms 
within the hCGβ coding genes and their effect on early pregnancy success until 
now. 
DNA copy number variants (CNVs) involving DNA rearrangements of 
>50 bp in size have been proposed to explain heritability of various complex 
diseases due to large coverage of the human genome (up to 30%) (Redon et al. 
2006; Mills et al. 2011). Only few studies have addressed the contribution of 
CNVs in the manifestation of reproductive disorders, including a single CNV 
screening focusing on placental samples of RM cases (Rajcan-Separovic et al. 
2010). Genome-wide profiling of CNVs among parents affected by the disease 
may prove as a powerful tool in mapping novel genetic biomarkers affecting the 
predisposition to RM independently but also in consort. 
In this thesis, the review of literature provides up to date information on the 
current knowledge of risk factors and genetic association studies of RM 
performed at fine-scale and global level. A comprehensive overview of the 
12 
structural and functional characteristics of hCG, its β-subunit and hCGβ coding 
genes is provided and the contribution of CNVs in common diseases and 
pregnancy complications is reviewed. 
The experimental part of the thesis aimed to map the fine-scale and global 
determinants of genetic susceptibility to RM setting the genetic diversity of 
hCGβ genes and global CNV profile as the examples. The research focused on 
firstly, the local genomic landscape of LHB/CGB gene cluster and evolutionary 
factors shaping the diversity of CGB genes in the context of RM. Fine-scale 
analysis of polymorphisms in two major hCGβ genes CGB5 and CGB8 as 
promising RM candidate genes was performed in three North European 
populations and the structural and functional effect of three non-synonymous 
mutations identified within the genes was addressed. Secondly, the impact of 
CNVs on the manifestation of RM was elucidated at the genome-wide scale and 
novel independent genetic biomarkers of RM were inferred from the global 
CNV profile. An improved map of genetic determinants and current status of 
research on the etiology of RM is discussed in the light of the findings provided 
in this thesis. 
  
13 
1. REVIEW OF LITERATURE 
1.1. Dynamics and challenges of human pregnancy  
Human pregnancy is a unique intricate system that involves maternal 
acceptance of an organism foreign by the molecular and genetic build, estab-
lishment of a transient invasive organ placenta and a complex interplay of 
maternal and fetal signals balancing between the maternal needs and fulfilling 
the fetal requirements. Well-balanced communication and timely progression of 
early stages of pregnancy are crucial for achieving a normal full term birth.  
Hemochorial placentation defined by the direct contact of fetal chorion with 
maternal bloodstream is characteristic to humans, higher primates, rabbit and 
rodents, however the advanced invasiveness of placentation is unique to humans 
(Enders and Carter 2004). Following the implantation of an embryo, the 
extraembryonic trophoblast cells proliferate and form syncytiotrophoblast cells 
covering the villous trees and give rise to non-proliferative extravillous 
trophoblast cells that adopt an invasive phenotype and induce remodeling of 
maternal uterine and vascular tissues (Norwitz et al. 2001; Red-Horse et al. 
2004). As the pregnancy progresses, the increasing surface of the branching 
placental chorionic villi is in direct contact with maternal blood providing 
access to nutritional, gas and waste exchange in response to the growing needs 
of the developing fetus. Successfully formed maternal-fetal interface is able to 
adapt to the changing environment and effectively resolve the challenges of 
pregnancy. Inadequate implantation, shallow placentation or reaction to stress 
factors (e.g. oxidative stress) may give rise to infertility or pregnancy compli-
cations several of which are largely human-specific, such as preeclampsia and 
recurrent miscarriages (Norwitz et al. 2001; Jauniaux et al. 2006). Some 
disorders may persist even after parturition and have an adverse impact on the 
long term maternal health by invoking cardiovascular and autoimmune diseases, 
metabolic syndrome and early mortality (Clifton et al. 2012). 
 
1.1.1. Prerequisites of early pregnancy success 
Balance and correct timing of the multitude of pathways regulating the first 
post-conception weeks are essential for successful establishment and sub-
sequent course of pregnancy. Low chance of natural conception per menstrual 
cycle (30%) has been observed in humans with 60% of pregnancy losses 
occurring already prior to clinical diagnosis of pregnancy highlighting the 
selective nature of the implantation and placentation stages (Zinaman et al. 
1996; Macklon et al. 2002).  
The timely progression of blastocyst implantation (within approximately 7 – 
10 days after ovulation) is strictly regulated by a bi-directional interplay 
between maternal and blastocyst signals (Teklenburg et al. 2010). The induction 
of endometrial receptivity window when the uterus supports implantation, 
promotion of blastocyst attachment and differentiation of endometrial cells into 
4
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decidua cells are mediated via a complex signaling network involving ovarian 
hormones, cytokines, growth factors, adhesion molecules and transcription 
factors (e.g. progesterone, estrogen, HB-EGF, KLF5, MSX1/2, LIF) (Norwitz et 
al. 2001; Cha et al. 2012). Failed or delayed implantation may lead to in-
/subfertility or early pregnancy loss, respectively, but also predispose to late 
obstetric complications such as preeclampsia (Figure 1) (Wilcox et al. 1999; 
Leach et al. 2002; Cha et al. 2012). Interestingly, it has recently been noted that 
unexpectedly large proportion of women affected by repeated early miscarriage 
(41% versus predicted 8%) are not sub- but super-fertile and achieve pregnancy 
within only couple of cycles (Salker et al. 2010). The phenomenon has been 
attributed to impaired natural embryo selection, whereby uterine environment 
allows the implantation of unviable embryos (Teklenburg et al. 2010).  
The final outcome of human pregnancy largely depends on the invasion of 
cytotrophoblast cells to an adequate depth in the uterus accompanied by 
remodeling of uterine spiral arteries and transformation into low-resistance 
vascular network (Jauniaux et al. 2006). Limited endovascular invasion has 
been related to suboptimal blood flow, subsequent hypoxia and tissue damage 
leading to the manifestation of preeclampsia or intrauterine growth restriction 
(Kaufmann et al. 2003). On the other hand, excessive placental invasion and 
abnormal attachment to maternal myometrium (placenta accreta/increta) that 
may even reach maternal organs (placenta percreta) is a serious obstetric 
complication with a risk of severe post-partum haemorrhage (Jauniaux and 
Jurkovic 2012). The advanced invasiveness characteristic to human hemo-
chorial placentation has been correlated with the evolution of hyper-
glycosylated human chorionic gonadotropin (hCG-h) in primate lineage 
expressed by invasive extravillous trophoblasts in early pregnancy (Jauniaux et 
al. 2006; Cole 2009; Guibourdenche et al. 2010). Concurrently, placental 
insufficiency due to low expression of hCG-h has been implicated in both early 
and late pregnancy disorders, such as early pregnancy loss and preeclampsia 
(Kovalevskaya et al. 2002; Keikkala et al. 2013).  
It has been shown that the largest proportion of genes upregulated in the 
human decidua cells in response to the paracrine signals of an implanting 
trophoblast are related to immune response at the feto-maternal interface (Hess 
et al. 2007). Maternal immune tolerance to the semi-allogeneic embryo 
expressing paternal antigens has been most extensively studied in normal 
pregnancy but also in relation to pregnancy complications (Guleria and Sayegh 
2007; Redman and Sargent 2010). In this feto-maternal immune system 
communication, critical role has been attributed to uterine natural killer (NK) 
cells that constitute 40% of cells in the decidua (CD56brightCD16– NK subset) 
and promote trophoblast invasion and angiogenesis (Moffett-King 2002; Hanna 
et al. 2006). Uterine NK cells express an array of killer immunoglobulin-like 
receptors (KIR) that mediate the trophoblast recognition via binding MHC class 
I molecules (HLA-E, HLA-C and HLA-G) expressed on extravillous 
trophoblasts. Distinct KIR receptor-ligand combinations have been associated 
15 
with increased risk of early pregnancy loss and preeclampsia (Hiby et al. 2004; 
Hiby et al. 2008; Faridi and Agrawal 2011). 
Upon successfully passing the selection windows at implantation and 
meeting all the prerequisites and challenges of a pregnancy, 30% of conceptions 
are estimated to reach live birth (Macklon et al. 2002). 
 
 
Figure 1. Cause-and-effect scenarios in human pregnancy disorders as proposed by 
(Cha et al. 2012). Deviations in the timing and signaling of early pregnancy stages may 
lead to in-/subfertility, early pregnancy loss or give rise to late pregnancy disorders due 
to subsequent placental insufficiency or shallow invasion. IUGR, intrauterine growth 
restriction. 
 
1.1.2. Recurrent early pregnancy loss 
A sporadic miscarriage is the most common pregnancy complication affecting 
approximately quarter of all women at least once in their lifetime and up to 15% 
of all clinically recognized pregnancies (Wilcox et al. 1988; Stirrat 1990). In 
3% of fertile couples, three or more consecutive early pregnancy losses occur 
before gestational week 22, defined as recurrent miscarriage disease (RM) 
(Christiansen et al. 2008). In patients diagnosed with RM, each subsequent 
16 
pregnancy is accompanied with an increased risk of not only miscarriage but 
also other obstetric complications such as preterm birth or small for gestational 
age newborns (Ogasawara et al. 2000; Jivraj et al. 2001; van Oppenraaij et al. 
2009). It is a distressing disease for the affected couples with approximately 
half of the cases remaining unsolved due to the complex etiology involving a 
spectrum of known but also as yet unidentified risk factors (reviewed in 
(Christiansen et al. 2008)). 
 
1.1.2.1. The heterogeneity of RM etiology 
The major cause of sporadic early miscarriages (in up to 75% of cases) is fetal 
chromosome abnormalities associated with continuously increasing age of 
women postponing childbearing to late 30s and early 40s in western countries 
(Philipp et al. 2003; Group 2010). Although high maternal age is also a risk 
factor in RM, other causes predominantly drive this disease as the chance of 
having an early pregnancy loss due to large chromosomal alterations is 
decreasing with an increasing number of miscarriages in a couple (Figure 2) 
(Ogasawara et al. 2000). The etiology of RM is heterogeneous and involves 
interplay between maternal, paternal and cumulative (placental/fetal) risk 
factors in pathways related to pregnancy establishment and maintenance.  
 
 
 
 
Figure 2. Rate of pregnancy success in women experiencing spontaneous miscarriages. 
(A) Pregnancy outcome depending on the maternal age in women with 2 or more 
miscarriages (adapted from (Matthiesen et al. 2012)). (B) Pregnancy success and the 
chance of observing fetal normal karyotype in women with 2 or more miscarriages and 
with average age of 31 years (based on (Ogasawara et al. 2000)). 
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The main factors studied in association with RM susceptibility include 
(reviewed in detail in (Pandey et al. 2005; Christiansen et al. 2006; Christiansen 
et al. 2008; Larsen et al. 2013)) 
 thrombophilic disturbances that contribute to thrombosis of placental vessels 
leading to placental infarctions  
 excessive inflammatory processes causing increased apoptosis and 
pregnancy failure 
 reproductive tract infections (e.g. HIV, malaria) triggering the inflammation 
of the uterine lining that disrupts embryo implantation and growth 
 autoimmune (e.g. antiphospholipid syndrome) and alloimmune (couple’s 
immunologic mismatch) factors leading to maternal rejection of the fetus  
 anatomical disorders (e.g. uterine malformations) 
 endocrine dysfunction (e.g. thyroid dysfunction) 
 sperm DNA fragmentation introducing deleterious DNA damage to the 
developing embryo 
 impaired embryo selection by maternal decidua 
 oxidative stress damaging feto-maternal tissues 
 
For many of the RM risk factors studied, the association with the disease is 
weak and/or the underlying mechanism has remained unclear (reviewed in 
(Christiansen et al. 2008; Larsen et al. 2013)) highlighting the need for further 
research to map and describe all the risk factors of this multifactorial disease  
 
1.1.2.2. Defining the genetic component of RM  
(also reviewed in Ref. I) 
Contribution of genetic susceptibility to the etiology of RM has been ac-
knowledged and up to 2-fold higher occurrence of the disease has been reported 
within the affected families compared to control population (Christiansen et al. 
1990; Kolte et al. 2011). Due to lower prevalence of large chromosomal abnor-
malities in miscarried embryos of RM patients compared to sporadic mis-
carriages (Ogasawara et al. 2000), other types of genetic variation (e.g. sub-
microscopic changes) likely contribute to the manifestation of the disease. Most 
studies addressing the genetic susceptibility to RM have used a candidate gene 
based approach by screening polymorphisms and mutations in genes with 
known functional effect on RM and/or pathways related to pregnancy 
establishment and maintenance. Currently, approximately 100 candidate genes 
have been targeted with the largest attention given to factors leading to throm-
bophilic, inflammatory and immunologic disturbances at the feto-maternal 
interface (Table 1 in Ref I).  
Like other thrombophilic mutations, the most common variants G1691A in 
factor V (Leiden mutation) and G20210A in prothrombin, may contribute to the 
excessive blood coagulation and impaired placental blood circulation leading to 
5
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increased risk of early pregnancy loss in the mutation carriers (Dizon-Townson 
et al. 1997). Although both mutations are routinely tested in the clinical setting 
and have been positively associated with RM in most studies, the odds ratio 
(OR) ranges considerably (from 0.5 to 18) due to the heterogeneous nature of 
the phenotype and instead, a stronger association has been observed for late 
pregnancy loss (Rey et al. 2003; Kovalevsky et al. 2004; Robertson et al. 2006). 
Similarly, the genes regulating the balance between the action of pro-
inflammatory (e.g. TNFα, IFNγ) and anti-inflammatory factors (e.g. IL6, IL10) 
at the feto-maternal interface have been studied extensively but have gained 
inconclusive results (Daher et al. 2003; Bombell and McGuire 2008). Due to 
weak or no impact of the studied polymorphisms, it has been proposed that 
instead of individual mutations, a combination and accumulation of throm-
bophilic and inflammation related genetic variants may shape the cumulative 
risk of RM (Rey et al. 2003; Jivraj et al. 2006). 
As the fetal cells are expressing antigens of paternal origin, the maternal 
rejection of the ‘foreign’ fetus is potentially one of the major causes leading to 
miscarriage event (Wilczynski 2006). This condition of allograft rejection is bi-
directional defined by maternal recognition and fetal presentation of paternal 
antigens and thus the genetic contribution of both counterparts has been 
addressed. For example, the allelic composition and presence of 14 bp insertion 
in the human leukocyte antigen HLA-G gene, the fetal genetic determinant 
expressed by extravillous cytotrophoblasts at the feto-maternal interface 
(Kovats et al. 1990), has been associated with the risk of RM, however the 
results are inconsistent (Aldrich et al. 2001; Hviid et al. 2004; Aruna et al. 2010; 
Wang et al. 2013). The cumulative effect of maternal recognition and presented 
fetal antigens has also been suggested as promising genetic factors describing 
susceptibility to RM, for example increased HLA-sharing between couples/ 
mother-fetus or specific interaction of killer immunoglobulin-like receptors 
(KIR) on maternal uterine NK cells and fetal HLA-C on the trophoblast cells. 
However, no clear consensus has also been reached for these findings (Witt et 
al. 2004; Beydoun and Saftlas 2005; Hiby et al. 2010; Kolte et al. 2010; 
Moghraby et al. 2010).  
The inconclusive or controversial results of the numerous candidate gene-
based SNP studies highlight the complexity of the studied phenotype and 
potentially low impact of single nucleotide variants in the manifestation of RM. 
It should be noted that many of the studies were also underpowered due to 
narrow study setup (only affected mothers) and insufficient number of study 
subjects to detect genetic variants of small effect size and/or with low 
population-specific prevalence (Ref. I). Thus, increasing the sample size, 
addressing both the maternal and paternal contribution to the disease and/or 
other types of variation in association with RM would prove beneficial. 
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1.1.2.3. Hypothesis-free ‘omics’ approach  
in screening for novel RM risk factors 
Unlike candidate gene based studies, the powerful tools of genome/ 
transcriptome/proteome-wide analyses would enable the identification of novel 
genes and pathways essential in early pregnancy and modulating the risk to RM. 
In recent years, a number of studies have addressed various levels of variation 
shedding light on this heterogeneous phenotype. 
 
Genomics 
Two genome-wide studies have been reported searching for novel RM-
associated genomic loci among the cases with unexplained RM. In a pilot study 
performed in unrelated Han Chinese patients and fertile controls, three micro-
satellite markers at 6q27, 9q33.1 and Xp22.11 were significantly associated 
with RM (Li et al. 2010). At 9q33.1, two potential RM candidate genes were 
proposed, the TNFSF8 and TNFSF15 belonging to the tumor necrosis factor 
(TNF) ligand family implicated in early pregnancy loss in mice (Erlebacher et 
al. 2004). Four additional genomic regions (3p14.2, 6q16.3, 9p22.1 and 
11q13.4) that did not overlap with the results by Li et al. (2010) were revealed 
in a linkage study undertaken in Danish sibling pairs affected by RM (Kolte et 
al. 2011). No SNP-based genome-wide association studies (GWAS) extensively 
used for identification of the genetic component of complex diseases have been 
performed for RM phenotype. The informative value of GWAS in the 
multifactorial RM remains unclear due to expected small effect sizes of indi-
vidual genetic variants as also demonstrated for other reproductive traits 
(Montgomery et al. 2013). 
Increasing evidence suggests that genomic imprinting mediating the 
expression of parent-specific alleles regulates the fetus- and placenta-specific 
genes and pathways (Nelissen et al. 2011; Novakovic and Saffery 2012). 
Aberrant gene methylation profiles have been linked to various obstetric dis-
orders such as small for gestational age, intrauterine growth restriction, 
preeclampsia and gestational trophoblastic disease (Xue et al. 2004; Guo et al. 
2008; Diplas et al. 2009; Yuen et al. 2009) but also recurrent miscarriage. In 
addition to one candidate-gene based study identifying aberrant methylation of 
hCG β-subunit coding CGB5 gene in three cases with RM (Uuskula et al. 2010), 
a genome-scale methylation analysis of chromosomally normal miscarried 
chorionic villi from RM women has been reported (Hanna et al. 2013). 
Alternative global methylation patterns were observed among the RM cases 
when compared to normal chorionic villi from elective abortions and altered 
methylation levels were subsequently confirmed for distinct loci, such as AXL 
(receptor tyrosine kinase) and DEFB1 (defensin β 1). 
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Transcriptomics 
A whole transcriptome analysis of maternal decidua or placental/fetal tissues 
may provide novel insights on pathways and specific genes with critical 
functions in implantation and maintenance of pregnancy. Although the 
expression of pre-selected genes in chorionic villi (Baek et al. 2002; Choi et al. 
2003) and endometrium (Lee et al. 2007) of RM cases has been addressed, only 
two studies have targeted the global transcriptome profile of these tissues. 
Differential gene expression analysis of the decidual tissue of women suffering 
from RM and undergoing a miscarriage confirmed the major contribution of 
pathways and genes related to immune response (23% of dysregulated genes) 
but also cell signaling (18%) and cell invasion (17.1%) in the reoccurrence of 
early pregnancy loss (Krieg et al. 2012). In the miscarried placental tissue of 
RM cases, significant overexpression of TNF-related apoptosis-inducing ligand 
(TRAIL) and inflammatory marker calprotectin (S100A8) were identified (Rull 
et al. 2013). The increased level of TRAIL protein has also been reported for 
maternal serum (Agostinis et al. 2012; Rull et al. 2013) and S100A8 mRNA in 
the maternal decidua (Nair et al. 2013) of women affected by recurrent early 
pregnancy loss thus potentially representing novel biomarkers of RM disease. 
Additional level of regulation in placental gene expression may be provided 
by short non-coding RNAs implicated in the post-transcriptional control of 
pathways related to male and female reproductive traits (Hawkins et al. 2011). 
Although not directly studied in recurrent miscarriages, differential microRNA 
(miRNA; ~22 nucleotides) profile has been reported for the cases of repeated 
implantation failure undergoing in vitro fertilization (IVF) procedures (Revel et 
al. 2011), indicating the potential contribution of miRNAs in the manifestation 
of early pregnancy loss. 
 
Proteomics 
In order to determine novel or confirm known RM risk factors at the proteome 
level, follicular fluid of three RM cases compared to three multiparous fertile 
controls was addressed with a combination of two-dimensional gel elec-
trophoresis and mass spectrometry by (Kim et al. 2006). Aberrant expression of 
five proteins was observed in the follicular fluid of which the angiotensinogen, 
complement component C3c chain E and coagulation factors fibrinogen γ and 
antithrombin were subsequently also confirmed to be downregulated in the 
chorionic villi tissue samples thus potentially affecting embryo development or 
placental function. The strength of proteome analysis was further underlined 
when similar approach was applied for the maternal serum of RM women 
identifying an additional potential biomarker, the acute-phase inflammation 
related ITI-H4 (Kim et al. 2011). 
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1.2. Human chorionic gonadotropin,  
the ‘pregnancy hormone’ 
One of the key factors essential in implantation and early pregnancy 
maintenance is the placental human chorionic gonadotropin also termed as the 
‘pregnancy hormone’. hCG is produced already by an 8-cell blastocyst prior to 
implantation (Lopata and Hay 1989) and upon reaching mother’s circulation it 
is used as an early pregnancy biomarker in conventional pregnancy tests. The 
concentration of hCG doubles every two days until peaking at gestational weeks 
9–11 and large inter-individual variation in the levels of hCG during pregnancy 
has been documented (Fig. 6B in Ref. II) (Hay 1988). Nevertheless, critically 
low amounts in maternal circulation have been related to adverse pregnancy 
outcome such as early spontaneous miscarriage or ectopic pregnancy (Korhonen 
et al. 1994; Rull and Laan 2005).  
A variety of functions have been attributed to the pleiotropic hormone hCG 
since early pregnancy that include supporting progesterone production by 
corpus luteum until the luteo-placental shift and independent expression of 
progesterone by the placenta but also promoting angiogenesis, trophoblast 
invasiveness and decidualization of endometrium, stimulating fetal testicular 
testosterone production and regulating maternal immunotolerance (Huhtaniemi 
et al. 1977; Zygmunt et al. 2002; Kayisli et al. 2003; Guibourdenche et al. 2010; 
Kajihara et al. 2010; Tsampalas et al. 2010; Schumacher et al. 2013). 
Alternative functions and sites of expression at lower amounts have been 
reported for assembled hCG and/or free hCG subunits in normal non-tropho-
blastic tissues such as pituitary, seminal fluid or secretory endometrium 
(Hoermann et al. 1995; Berger et al. 2007; Zimmermann et al. 2012). Also, 
increased level of circulatory hCG/hCGβ production in non-pregnant organism 
is the marker of invasive tumour progression, including bladder and gastroin-
testinal cancers (reviewed in (Stenman et al. 2004)). The parallel effect of hCG 
in implantation/placentation and cancerogenesis is attributed to its ability to 
modulate pathways essential in both processes, e.g. promoting cell invasion, 
angiogenesis and escape of immune surveillance (reviewed in (Holtan et al. 
2009)). 
 
1.2.1. Structural characteristics of hCG 
Human chorionic gonadotropin belongs to the family of heterodimeric glyco-
sylated gonadotropins together with luteinizing hormone (LH) and follicle 
stimulating hormone (FSH), all formed by non-covalent association of common 
α-subunit and unique β-subunit that defines their functional properties and 
binding to specific receptor (Morgan et al. 1975; Pierce and Parsons 1981). 
Although LH and hCG act via the same ubiquitously expressed human 
luteinizing hormone/chorionic gonadotropin receptor (hLH/CGR) (reviewed in 
(Ascoli et al. 2002)), hCG is discerned by mainly placenta-specific expression 
(syncytiotrophoblast cells) and increased biopotency in induction of cAMP 
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signaling pathway (Casarini et al. 2012). Recently, stimulatory effects inde-
pendent of hLH/CGR have also been proposed for hCG isoforms in angio-
genesis and trophoblast invasion (Berndt et al. 2013; Lee et al. 2013). 
The hCG α- (length 116 amino acids) and β-subunits (145 amino acids) form 
a similar tertiary structure determined by five cystine bonds in hCGα and six in 
hCGβ (Lapthorn et al. 1994). Both subunits are comprised of three hairpin loops 
held together by three disulfide bonds that form a characteristic cystine knot 
motif which is a highly conserved structural feature also found among growth 
factors such as transforming growth factor-β2, nerve growth factor and platelet-
derived growth factor-BB (Murray-Rust et al. 1993; Lapthorn et al. 1994). 
Disruption of the cystine knot forming disulfide bonds in hCGβ (Cys38-Cys90, 
Cys34-Cys88 and Cys9-Cys57) in vitro has a detrimental effect on folding, 
assembly and subsequently function of the protein (Bedows et al. 1993; Mishra 
et al. 2003). Concordantly, no in vivo mutations affecting the production of hCG 
hormone have been characterized likely due to resulting compromised fertility 
and embryo’s viability. 
The stability of hCG is determined by two N-linked and four O-linked 
oligosaccharide chains specific to the hCGβ protein that prolong the hormone’s 
half-life to >24 hours compared to 3–4 hours for FSH and only <1 h for LH 
(Table 1 in Ref. II) (Morgan et al. 1975; Lapthorn et al. 1994). A hyper-
glycosylated form of hCG (hCG-h) with large complex glycan moieties has 
been described as the major form of hCG expressed by invasive extravillous 
cytotrophoblast during the first weeks of normal pregnancy and promoting early 
placentation process (Guibourdenche et al. 2010). Increased amounts of hCG-h 
have been detected in cases of testicular cancer, hydatidiform mole, choriocar-
cinomas and trisomy 21 (Elliott et al. 1997; Cole et al. 1999; Lempiainen et al. 
2012), whereas reduced levels have been observed in early pregnancy loss and 
preeclampsia (Kovalevskaya et al. 2002; Keikkala et al. 2013). 
 
1.2.2. Genomic context and evolution  
of hCGβ genes (also reviewed in Ref. II) 
In humans, the hormone-specific β-subunit of hCG is encoded by four CGB 
genes (CGB, CGB5, CGB7 and CGB8) with 97–99% DNA sequence identity 
that give rise to an almost identical hCGβ protein (98 – 100%) in the placenta 
(Bo and Boime 1992; Hollenberg et al. 1994). The hCGβ genes are co-located 
with the LHβ gene (LHB) and two putative pseudogenes (CGB1 and CGB2) in 
tandem and inverted orientations within a common gene cluster (approximately 
50 kb) at 19q13.32 (Figure 3) (Policastro et al., 1986).  
The CGB genes have likely evolved by the expansion of the ancestral LHB 
gene duplicons in the primate lineage as consistently increasing number of CGB 
genes is evident among the primates today reaching five gene copies in 
chimpanzee and six in the human genome (Figure 3; Ref II) (Maston and 
Ruvolo 2002; Hallast et al. 2008). The duplicate CGB gene acquired a 
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frameshift mutation in the last exon elongating the protein by 24 amino acids 
(termed as the C-terminal extension) that introduced the attachment sites for 
novel 0-linked oligosaccharides and subsequently increased the half-life of CG 
(Maston and Ruvolo 2002). Nevertheless, the homology between human LHβ 
and CGβ proteins has remained at >80% (Pierce and Parsons 1981). Alterations 
in the promoter region transferred the expression of the novel gonadotropin 
from pituitary to placenta and from non-pregnant to pregnant organism 
(Hollenberg et al. 1994).  
 
 
 
Figure 3. Genomic context of the LHB/CGB gene cluster in primates. The figure was 
drawn based on Ensembl database (http://www.ensembl.org/; Release 54). Boxes 
denote the genes and triangles above or below them point to the direction of 
transcription. The black boxes indicate CGB, white LHB and grey neighbouring genes. 
The CGB genes of rhesus macaque (Macaca mulatta) and common marmoset 
(Callithrix jacchus) are indicated as CGB A-C, since their ancestral status relative to the 
human CGB genes is unknown (reviewed in Henke and Gromoll 2008; Hallast et al. 
2009) (Ref. II). 
 
The CGB1 and CGB2 genes further diverged from the CGβ genes due to 
replacement of classical CGB 5’ upstream region with a novel DNA sequence 
changing the open reading frame and promoting speculations on the existence 
of a novel protein that bears no resemblance to hCGβ (Bo and Boime 1992; 
Hallast et al. 2007). Although the expression of CGB1/2 splice variants has 
been detected in placenta, testis and pituitary (Dirnhofer et al. 1996; Rull and 
Laan 2005; Parrott et al. 2011) and at increased levels in ovarian and breast 
cancer tissues (Giovangrandi et al. 2001; Kubiczak et al. 2013), only the 
classical hCGβ protein has been identified in testis possibly induced by the 
active transcription of snaR-G genes located in the novel inserted sequence 
upstream of CGB1/2 (Parrott et al. 2011). The functional relevance of the 
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CGB1/2 genes and the existence of the hypothetical CGB1/2 protein are 
currently under debate. 
The appearance of CGB genes has been correlated with the evolution of 
increasingly invasive hemochorial placenta in primates as CG mediates the 
trophoblast invasion and placental anchoring into maternal tissues (Maston and 
Ruvolo 2002; Cole 2009). Concordantly, inadequate placental invasion and 
hCG production may lead to obstetric complications (e.g. pre-eclampsia, 
spontaneous miscarriage) largely unique to humans as the representatives of 
most advanced hemochorial placentation (Jauniaux et al. 2006). 
 
1.2.3. hCGβ genes as candidate risk loci in pregnancy failure 
The human CGβ genes exhibit a highly variable transcriptional activity in the 
placenta with CGB5 and CGB8 providing the largest contribution to the pool of 
hCGβ transcripts (up to 82%) (Bo and Boime 1992; Miller-Lindholm et al. 
1997; Rull and Laan 2005). The cumulative expression level of the hCGβ genes 
during the course of pregnancy is in good correlation with the total amount of 
the hormone as the rate-limiting step in hCG production is the formation of the 
hCGβ protein (Fig. 6 in Ref. II) (Huth et al. 1992). The clinical significance of 
the hCGβ genes is indicated by the decreased placental expression among the 
cases of recurrent miscarriage (Rull and Laan 2005) or excessive expression in 
ectopic and molar pregnancy (Rull et al. 2008). The requirement of balanced 
biallelic transcription of maternal and paternal alleles has been observed for 
early pregnancy, whereas methylation allelic polymorphism patterns in the 
CGB5 gene whereby paternal alleles have gained methylation has been 
associated with recurrent miscarriage (Uuskula et al. 2010).  
Addressing the genetic variation of the CGB genes in relation with obstetric 
complications has been challenging due to high DNA sequence similarity 
between gene copies (up to 99%), imprecise map of gene-specific poly-
morphisms and likely compensatory effect of the multi-copy hCGβ genes. It is 
thus not surprising that no genetic variants with phenotypic effect have been 
reported in CGB genes until the studies reported in this thesis (also reviewed in 
Ref. II). Further research is needed to elucidate the genetic factors underlying 
the transcriptional variability of CGB genes seen in various pregnancy disorders 
but also cancer. 
 
 
1.3. DNA copy number variation 
Copy number variants (CNVs) (Figure 4) represent deletions, duplications or 
inversions of > 50 bp DNA sequence cumulatively covering up to 12–30% of 
human genome compared to 1% altered by SNPs (Redon et al. 2006; Zhang et 
al. 2009; Mills et al. 2011). Due to the large genomic coverage, CNVs introduce 
substantial dynamics and interindividual variation to the genome not only 
among humans but also other mammals, including chimpanzee, rhesus 
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macaque, dog, mouse and rat (Graubert et al. 2007; Kehrer-Sawatzki and 
Cooper 2007; Guryev et al. 2008; Lee et al. 2008; Conrad et al. 2010; Berglund 
et al. 2012), and in Drosophila melanogaster (Emerson et al. 2008). Recent 
technological advances such as next-generation sequencing have further 
improved fine-mapping of the CNV profiles in human genome facilitating the 
accurate copy number detection of even complex genomic regions (Alkan et al. 
2009; Mills et al. 2011). 
It has been estimated that CNVs disrupt around 13% of human RefSeq genes 
(McCarroll et al. 2008; Conrad et al. 2010) and approximately 18% of 
variability in gene expression may be attributed to these DNA variants (Stranger 
et al. 2007). Concordantly, a growing number of structural DNA variations have 
been implicated in benign phenotypic traits (e.g. human amylase gene variation) 
(Perry et al. 2007), rare genomic syndromes (e.g. Potocki-Lupski syndrome) 
(Potocki et al. 2000) and common disease susceptibility (Girirajan et al. 2011a). 
Both increased global burden of CNVs and distinct CNV loci have been linked 
to several complex disorders pointing to considerable contribution of these 
genetic variants in modulating individual’s disease risk. 
 
 
 
 
Figure 4. Schematic represen-
tation of a DNA copy number 
variation (CNV). In case a CNV 
region involves a dosage sensi-
tive gene/regulatory region 
(arrow), deletion (individual X), 
tandem duplication (Z) or a more 
complex genomic rearrangement 
(W) may lead to a disease among 
the CNV carriers. 
 
 
1.3.1. CNVs in common diseases 
1.3.1.1. Hypothesis-free global genomic profiling of CNVs 
Genome-wide screening for structural variations has been undertaken in an 
attempt to map the global ‘risk profile’ or determine particular categories of 
CNVs predisposing to common disease. Due to likely disease-conferring risk, 
rare CNVs have been preferentially addressed by numerous studies and several 
rare case-specific rearrangements have been implicated in the occurrence of a 
common disease. There is a publication bias towards the neuropsychiatric 
disorders likely due to the assembled consortia and access to large number of 
cases needed for increased statistical power of genome-wide analysis, 
particularly when targeting rare CNVs. 
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Increased burden of de novo and rare (<1%) CNVs among the affected 
individuals has been reported for several neuropsychiatric disorders, including 
autism (Pinto et al. 2010), schizophrenia (Consortium 2008; Walsh et al. 2008; 
Vrijenhoek et al. 2008; Vacic et al. 2011), bi-polar disorder (Malhotra et al. 
2011) and a combined analysis of autism, intellectual disability and dyslexia 
(Girirajan et al. 2011a). Several novel candidate genes increasing the disease 
risk have been identified in these CNVs, including VIPR2, NRXN1 and 
SHANK2. An enrichment of genes affecting neuronal signaling and develop-
ment pathways has also been observed potentially suggesting that co-occurrence 
of individually rare CNVs may cumulatively increase the risk of a neurode-
velopmental disorder (Walsh et al. 2008; Pinto et al. 2010). Concurrently, a 
two-hit model has been proposed, whereby at least two mutational hits of large 
(>500 kb) rare CNVs are needed for the manifestation of a neuropsychiatric 
disease (Girirajan et al. 2010; Girirajan et al. 2012).  
In addition to neurodevelopmental disorders, genome-wide association 
studies involving both rare and common CNVs have been performed for 
complex diseases having a large impact on public health. In severe obesity 
cases, burden of long (>100 kb or >500 kb) rare CNVs was reported and 
significant enrichment of deletion CNVs affecting genes of G-protein coupled 
receptors was observed (Bochukova et al. 2010; Wheeler et al. 2013). A 
genome-wide analysis of all CNV classes in eight common diseases has been 
applied by The Wellcome Trust Case Control Consortium in altogether 16000 
cases of bipolar disorder, breast cancer, coronary artery disease, Crohn’s 
disease, hypertension, rheumatoid arthritis, type 1 diabetes and type 2 diabetes 
(Craddock et al. 2010). CNVs in or near altogether three loci were associated 
with Crohn’s disease (IRGM), type 2 diabetes (TSPAN8) or with Crohn’s 
disease, rheumatoid arthritis and type 1 diabetes (HLA region). The association 
of HLA region with type 1 diabetes was further confirmed by an independent 
study identifying 11 risk conferring CNVs, including a deletion near HLA-DQ 
allele (Grayson et al. 2010). Recently, two studies have reported the impact of 
CNVs on human longevity, whereby either burden of large (≥500 kb) common 
deletions or CNVs involving genes that affect RNA alternative splicing were 
associated with decreased lifespan (Kuningas et al. 2011; Glessner et al. 2013). 
 
1.3.1.2. Targeted analysis of copy number variable genes 
Targeted analysis of several distinct copy number variable loci has been per-
formed in the context of common human diseases, majority of which are related 
to disturbances in the function of immune system and share the risk-associated 
loci. 
The complex structural variation of duplicate genes encoding alpha- and 
beta-defensins (DEFA and DEFB) has been mapped in detail in human 
population (Hollox et al. 2003; Aldred et al. 2005). As the multi-functional 
defensin proteins have an important role in innate system, copy number 
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variation of these genes has been studied in complex disorders and increased or 
decreased copy numbers have been associated with psoriasis (Hollox et al. 
2008; Stuart et al. 2012) and Crohn’s disease (Fellermann et al. 2006), 
respectively. 
Human Fcγ receptors are IgG-binding glycoproteins that are encoded by a 
duplicate gene family of FCGR genes and have been implicated in autoimmune 
and inflammatory diseases. Copy number variation of members of this gene 
family increases the risk of idiopathic thrombocytopenic purpura and systemic 
lupus erythematosus (Breunis et al. 2008;Fanciulli et al. 2007). The systemic 
lupus erythematosus disease has also been associated with CNVs involving 
complement component C4 genes (Yang et al. 2007) and interestingly, an 
epistatic effect was found between FCGR3B and CCL3L1 encoding for 
macrophage inflammatory protein (MIP)-1α influencing both systemic lupus 
erythematosus and rheumatoid arthritis (Mamtani et al. 2010). Susceptibility to 
human immunodeficiency virus (HIV) infection has been addressed with CNV 
studies although with contrasting results. Contribution of the gene dosage of 
CCL3L1, the human immunodeficiency virus-1 (HIV-1)-suppressive 
chemokine, has been debated (Gonzalez et al. 2005; Shao et al. 2007), whereas 
a positive association was observed for the relative amounts of activating and 
inhibitory KIR genes that control HIV-1 infection (Pelak et al. 2011). As the 
KIR gene family has been associated with a variety of human diseases and 
extensive copy number variability has been described in the region (Jiang et al. 
2012; Kusnierczyk 2013), other traits depending on KIR gene dosage are 
expected to be reported. 
As examples of non-immunomodulatory findings, triplication of trypsinogen 
gene (PRSS1) in patients of hereditary pancreatitis and recently, CNVs 
disrupting the AUTS2 gene of unknown function among the cases of neuro-
developmental disorders have been reported (Le Marechal et al. 2006; 
Nagamani et al. 2013) (reviewed in (Girirajan et al. 2011b)). 
 
1.3.2. CNVs in pregnancy complications 
In spite of the growing evidence of CNVs modulating the risk to various 
complex disorders, only few studies addressing the contribution of CNVs in 
pregnancy complications have been reported very recently. 
A combined GWAS and CNV analysis has been performed among the cases 
with pre-eclampsia, the pregnancy-related hypertension, and in normotensive 
females (Zhao et al. 2012). Although only deletion CNV regions were con-
sidered as potentially the most deleterious type of rearrangement in the original 
study, three CNVs with increased prevalence among white female cases 
compared to controls were identified (Table 1). A 15 kb deletion encompassing 
the PSG11 gene expressed during pregnancy by syncytiotrophoblasts was 
highlighted as potentially contributing to the occurrence of preeclampsia. The 
findings were not subsequently replicated among preeclamptic and normoten-
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sive Afro-Caribbean, Hispanic and European ancestry mothers, however, a 
number of novel candidate rearrangements were reported (Table 1) (Zhao et al. 
2013). Neither of the studies identified SNP associations of genome-wide 
significance likely due to the small number of analyzed cases. 
Single reports for recurrent miscarriage and stillbirth have been published, 
both addressing a small number of cases (n = 27 and 29, respectively) and 
largely relying on the reference dataset of common CNVs in the Database of 
Genomic Variants (DGV) in order to infer the potential impact of identified 
rearrangements on the disease (Table 1) (Ledig et al. 2010; Rajcan-Separovic et 
al. 2010; Harris et al. 2011). CNVs involving the PAPPA and HLA-DPA1 genes 
were implicated in the occurrence of stillbirths, whereas in recurrent 
miscarriage, two imprinted placental genes rearranged in the placental samples, 
TIMP2 and CTNNA3, were highlighted as novel potential candidates increasing 
the risk of early pregnancy loss (Rajcan-Separovic et al. 2010; Harris et al. 
2011).  
Like candidate gene-based studies, CNV analyses are sensitive to sample 
size, ethnic background and adequate definition of phenotype of the study 
subjects and thus, most of the currently reported studies on pregnancy 
complications are likely to underestimate the number and effect of CNVs 
modulating the risk to disease. Also, none of the published studies have 
addressed the couple’s cumulative susceptibility to disease, although both 
mother and father contribute to the fetal/placental genome and function (Table 
1). Further research is needed to elaborate on the findings and assess the 
contribution of CNVs in manifestation of pregnancy complications. 
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2. AIMS OF THE PRESENT STUDY 
The present thesis aimed to elucidate contribution of human genome variation at 
global and fine-scale level in modulating the genetic etiology of recurrent 
miscarriage (RM). The main research aims of the thesis were as follows: 
 
I. Fine-scale genome dynamics of duplicated LHB/CGB genes essential in 
fertility and early pregnancy maintenance (Ref. III) 
 Investigation of structural features and recombination patterns shaping 
the genomic landscape of the LHB/CGB gene cluster 
 
II. DNA single nucleotide variants in the hCG β-subunit coding genes CGB5 
and CGB8 in the context of RM disease  
 Screening for and association study of single nucleotide variants in the 
CGB5 and CGB8 genes in three North European populations (Ref. IV, 
V) 
 Testing the impact of identified missense mutations on the structural 
and functional features of hCGβ and hCG in vitro (Ref. VI) 
 
III. DNA copy number variants (CNVs) as novel genetic determinants of 
recurrent miscarriage (Ref. VII) 
 Investigation of genome-wide CNV profile and its effect on functional 
pathways in RM cases 
 Identification of novel common CNV regions conferring risk to RM 
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3. RESULTS 
3.1. Genome dynamics of human LHB/CGB  
gene cluster (Ref. II, III) 
Rationale of the study: 
The expression of the heterodimeric human chorionic gonadotropin (hCG) 
hormone in the placenta is of critical importance to the maintenance of early 
pregnancy. Due to the extensive sequence complexity and lack of detailed 
information on the polymorphisms of the gene family encoding the β-subunit of 
the hormone (CGB genes) the region has proven difficult to target in genomic 
approaches. This study was undertaken to describe the nature and origin of the 
diversity of the LHB/CGB gene cluster in order to promote further research of 
this region in the context of pregnancy success. 
 
3.1.1. Genomic structure of the LHB/CGB gene cluster  
To fine-map the genomic structure of the LHB/CGB gene cluster in silico, the se-
quence obtained from the NCBI GenBank database (http://www.ncbi.nlm.nih.gov; 
locus no NG_000019; June 26, 2002 release) was analyzed using web-based 
global alignment tools CLUSTALW (http://www.ebi.ac.uk/clustalw/) and 
BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) (Ref. III). The human LHB/CGB 
gene cluster includes the LHB gene (luteinizing hormone beta polypeptide; 
length 1.1 kb) encoding the LHβ protein expressed in pituitary, putative 
pseudogenes CGB1 and CGB2 (1.4 kb) and six CGB (chorionic gonadotropin, 
beta polypeptide) genes encoding the hCGβ subunit primarily expressed in 
placenta – CGB, CGB5, CGB7 and CGB8 (all 1.5 kb). The region is charac-
terized by not only extensive DNA sequence identity between the genes (97–
99% among the hCGβ genes, 92–93% when compared to LHB, 85% when 
compared to CGB1 and CGB2) but also between the intergenic regions (up to 
97%) (Figure 5). The gene cluster is closely bordered by functionally unrelated 
genes RuvB-like 2 (RUVBL2) and neurotrophin 5 (NTF5; now known as NTF4).  
The structural features currently seen among humans have likely arisen via 
several steps of duplication events involving the ancestral LHB giving rise to 
the CGB genes and part of the NTF5 gene that has spread into the intergenic 
regions (Figure 5). The duplicated intergenic Alu-rich fragment originating 
from NTF5 included the consensus Escherichia coli χ-sequence (GCTGGTGG) 
that has been associated with increased recombination and gene conversion 
activity (Smith 1988). The presence of χ-sites together with high content of Alu 
repetitive sequences in the intergenic regions (currently in humans 10–56%) 
may have cumulatively promoted the extensive rearrangement events in the 
primate lineage. The concept of duplication series in the evolution of this gene 
cluster is supported by the identification of various number of CGB genes in 
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other primates, such as chimpanzee (n = 5) (Hallast et al. 2008), rhesus 
macaque (n = 4) and common marmoset (n = 1) (Figure 3). 
 
 
Figure 5. Structure of the human LHB/CGB gene cluster. Identical color codes refer to 
highly homologous DNA sequences within the cluster. Genes (RUVBL2, LHB/CGBs, 
NTF5) are depicted as wide arrows in the direction of transcription with promoters as 
boxed arrows 5’ of the genes. Intergenic areas are marked as narrow lines, indicating 
also the direction of a segment, and broken arrows unite intergenic regions that share 
>75% of sequence identity. χ denotes the localization of χ-sequence. Int2 and Ex3 refer 
to intron 2 and exon3 in the NTF5 gene; the former is the source of intergenic regions 
between CGB genes, and the latter has given rise to NTF6 pseudogenes.  
 
3.1.2. Polymorphism density and gene conversion activity  
The diversity of the LHB/CGB genes was addressed by resequencing all genes 
except for CGB8 (inaccessible due to sequence complexity) in three 
populations: Estonians (n = 47), African Mandenka (n = 23) and Chinese Han 
(n = 25). In total, 191 SNPs where identified with only a small fraction 
represented in the dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) (Supplementary 
Table S1 in Ref. III). Although the level of diversity varied among the 
populations analyzed, the highest polymorphism density was mutually observed 
for the genes at the edges of the gene cluster (LHB, CGB and CGB7) (Figure 2 
in Ref. II; Table 1 in Ref. III). The peripheral genes LHB, CGB and CGB7 were 
also characterized by strong linkage disequilibrium (LD), whereas breakdown 
of LD was observed toward the center of the gene cluster (CGB1, CGB2, 
CGB5) (for Estonians, Figure 6A; Figure 3 in Ref. III). Two major gaps in LD 
were noted in all populations (between the CGB5 and CGB8 genes and between 
CGB and CGB2) potentially pointing to higher recombination activity in these 
regions.  
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The high sequence similarity between duplicated regions in the LHB/CGB 
cluster is the rich substrate for the phenomenon of gene conversion whereby 
DNA sequence information is transferred between a pair of highly identical 
sequences via the process of homologous recombination (Figure 4A in Ref. II). 
A directional transfer of gene conversion tracts was observed from the central 
CGB gene copies to the distal genes with the highest number of acceptor sites 
identified for CGB (n = 8) and CGB7 (n = 7) (Figure 2 in Ref. III) that also 
exhibited the highest polymorphism density and strongest LD. Gene conversion 
mechanism is likely the major force in shaping the diversity patters of the 
LHB/CGB region and spreading mutations that may modulate the function of 
the involved genes. 
 
3.1.3. Recombination rate and structural analysis  
of potential recombination ‘hot spot’ 
The recombination rate of the LHB/CGB gene cluster was assessed and 
recombination ‘hot spots’ were identified from unphased genotype data based 
on ‘λ’ that estimates by which factor the recombination rate between the loci 
exceeds the average background rate (Li and Stephens 2003). The value λ = 1 
corresponds to the absence and λ > 1 to increased recombination activity. In all 
populations studied, potential recombination ‘warm spots’ and ‘hot spots’ were 
identified in the regions overlapping with the sharp LD breakdown observed in 
the LHB/CGB cluster (Figure 3 in Ref. III). Among Estonians, the factor λ 
reached 2.36 for the potential recombination ‘warm spot’ between the CGB and 
CGB2 genes and 57.1 for the ‘hot spot’ between CGB5 and CGB7 (Figure 6A). 
In order to refine the location of the potential recombination ‘hot spot’ in the 
region between the CGB5 and CGB7 genes that includes CGB8 and has 
remained inaccessible to CGB8-specific PCR and sequencing methods due to 
high sequence complexity, I conducted a pilot study by applying a combination 
of long-range (8.3 kb) and nested PCRs and subsequent resequencing in 11 
Estonian populations samples. The analysis confirmed the weak LD in the 
region and fine-mapped the location of the recombination ‘hot spot’ in a <1 kb 
region between the CGB8 and CGB7 genes, embedded within an Alu-rich 
(~75% Alu-sequences) segment and 90–100 bp from the recombination-
associated χ – sequence (Figure 6B). The DNA structural analysis of the ‘hot 
spot’ identified palindromic Alu repeats in the region that could give rise to a 
stem-loop secondary structure with a 625 bp stem and single-stranded loop 
segment (222 bp) in the middle (Figure 6C) potentially promoting double-
strand breaks and subsequent recombination/gene conversion activity. Inverted 
repeats were also identified in the recombination ‘warm spot’ region between 
the CGB and CGB2 genes, however with a much longer spacer (2788 bp) which 
might lead to decreased stability of the secondary structure and decreased 
recombination rate.  
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3.2. DNA single nucleotide variants of CGB5 and  
CGB8 in the context of recurrent miscarriage 
3.2.1. SNP profile of the CGB5 and CGB8 genes  
in recurrent miscarriage (Ref. IV, V) 
Rationale of the study: 
Due to the irreplaceable role of hCG at the early stage of pregnancy, CGB genes 
encoding the hCG β-subunit are regarded as potential candidate genes for 
studying the genetic etiology of early pregnancy complications, such as 
recurrent miscarriage. The CGB5 and CGB8 genes that cumulatively provide up 
to 82% of hCG β-subunit transcripts in the human placenta (Miller-Lindholm et 
al. 1997; Rull and Laan 2005) likely have the largest effect on the quantity and 
quality of the hCG produced and are thus best candidates for addressing the role 
of this gene family in recurrent miscarriage. 
 
3.2.1.1. Screening for variants in Northern Europe 
The lack of comprehensive list of gene-specific polymorphisms for highly 
similar CGB5 and CGB8 (>92%, Ref. III) in the SNP databases prompted the 
full resequencing of these genes in RM case-control subjects from Northern 
Europe (Ref. IV). The 5’ upstream (up to –435 bp from the start site of mRNA 
sequence) and genic region (down to +1082 bp relative to the mRNA start site) 
of CGB5 and CGB8 were resequenced in 184 female RM cases and their male 
partners (≥3 consecutive miscarriages before gestational week 22; Estonia 
n = 99, Finland n = 85) and 195 fertile women as controls (at least one live birth 
in Finland or three in Estonia and no previous miscarriages; Estonia n = 95, 
Finland n = 100). In total, 71 SNPs were identified (49 in CGB5, 22 in CGB8; 
Table 1 in Ref. IV) with nearly absent LD between them in both populations 
(Figure 2 in Ref. IV) that is largely concordant with the LD breakdown in the 
middle part of the LHB/CGB cluster reported in Ref. III.  
 
3.2.1.2. Disease-related variants and haplotypes in CGB8 
The SNP profile analysis of CGB8 highlighted the potential functional 
relevance of the 5’ upstream region of the gene. The region involved only three 
SNPs (Table 1 in Ref. IV) compared to the 18 SNPs in the respective DNA 
stretch of CGB5 and was predicted to evolve under stronger functional 
constraints. Two neutrality tests were applied to explore observed versus 
expected distribution of SNPs and haplotypes – the Tajima’s D (the difference 
between observed (π) and expected (θ) diversity estimates) and Ewens-
Watterson homozygosity estimations (tests the observed allele frequency 
spectrum with the expected allele frequency spectrum under the neutral model 
(Hardy-Weinberg Equilibrium)). Both, the Tajima’s D statistic (DT = 2.29, 
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P <0.05) as well as Ewens-Watterson homozygosity test (P = 0.007) (Table 2) 
indicated a possible scenario of balancing selection driving the three apparently 
most efficient CGB8 promoter variants (H1, H3, H4 in Figure 7A) to high 
frequency in both populations (Supplementary Table S2 and Supplementary 
Fig. S2 in Ref. IV).  
 
 
 
Only one rare promoter variant H2 was identified in the 5’ upstream region 
defined by the minor allele A of SNP c8EF-4 (position relative to transcription 
start site) that was solely present in RM patients, one from Finland and two 
from Estonia (Cochran-Armitage trend test, P = 0.071; Figure 7A; Table 1 in 
Ref. IV). This polymorphism may potentially affect the expression of the CGB8 
gene as it is located (i) within the AP1-like sequence overlapping the hCGβ 
initiator element critical for basal transcription and (ii) downstream of the Ets-2 
binding site acting as a major enhancer of hCGβ gene expression (Ghosh et al. 
2003).  
Table 2. Neutrality tests of the CGB5 and CGB8 genes in fertile women and RM cases.  
 CGB5 CGB8 
 Full 
regiona 
5’upstream 
regionb 
Genic 
regionc 
Full 
regiona 
5’upstream 
regionb 
Genic 
regionc 
No of SNPs 46 17 29 23 3 20 
Fertile women
Tajima Dd –1.12980 –1.16944 –0.88132 –0.35277 2.29389* –0.96141 
P-value of Ewens-
Watterson Fe 
ns ns ns ns 0.007 
 
ns 
RM Patients 
Tajima Dd –1.23744 –1.23550 –0.91052 –0.56306 1.26879 –1.06361 
P-value of Ewens-
Watterson Fe 
ns ns ns ns ns ns 
aSNPs in 5’upstream and genic regions; bSNPs located in the region of –435 bp up to –1 bp from 
the start site of mRNA sequence; cSNPs located in mRNA seqence: +1 bp up to +1082 bp from 
the start site of mRNA sequence; dThe basis of the Tajima’s D statistics (DT) is the difference 
between observed (π) and expected (θ) diversity estimates: under neutral conditions π = θ and 
DT = 0; eThis statistic tests the observed allele frequency spectrum with the expected allele 
frequency spectrum under the neutral model (Hardy-Weinberg Equilibrium). 
*P = 0.0169; ns – non-significant (P > 0.05) 
 
 
Figure 7. Haplotype networks of predicted promoter variants in the 5’ upstream region 
of CGB8 (A) and CGB5 (B). Promoter variants were inferred from unphased genotype 
data using the Bayesian statistical method in the program PHASE 2.1.1. (Stephens et al. 
2001) and networks of inferred haplotypes were drawn with NEWTWORK 4.201 
software using the Median-Joining network algorithm (Bandelt et al. 1999). Singleton 
polymorphisms were excluded from the haplotype prediction analysis because of 
unreliable phasing. The size of each node is proportional to the haplotype frequency in 
the total dataset. The relative distribution of each haplotype among the RM cases 
(black) and fertile controls (white) is indicated. Haplotype nomenclature is shown in 
Supplementary Table S2 in Ref. IV. (A) Haplotype H2 defined by the minor allele of a 
proximal promoter mutation c8EF-4 was exclusively identified among RM patients in 
both Estonia and Finland. (B) The clade with haplotypes H1, H2, H10 and H11 carry 
the combination of minor alleles of four SNPs (c5-155C/c5-147del/c5-144C/c5-142A) 
that originates from the CGB8 gene and has a protective effect against RM. The 
locations of the four SNPs are indicated in the alignment of consensus DNA sequence 
of the LHβ and hCGβ genes. Positions are given according to the transcription start site 
of CGB5. 10
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Interestingly, the haplotype combining the minor alleles of c8EF-287 and c8EF-
186 was absent in the current dataset in spite of the relatively high minor allele 
frequencies (MAF) of the SNPs (25.2% and 39.7%, respectively). The 
discrepancy between observed (0%) and expected (10%) haplotype frequency 
may be explained by the localization of these SNPs within the binding sites of 
Sp1/AP-2 transcription factors residing in the hCGβ gene region critical for the 
trophoblast-specific expression as well as cAMP-responsiveness of the 
transcription (Albanese et al. 1991). Considering also that the CGB8 gene 
contributes most to the pool of hCGβ transcripts in the placenta (40%) (Rull and 
Laan 2005) it is thus likely that CGB8 is harboring the most optimally 
functioning promoter sequence of the hCGβ genes. 
 
3.2.1.3. Disease-related variants and haplotypes in CGB5 
The SNP profile of 5’ upstream region of CGB5 (in total, 18 SNPs) involved a 
motif of minor alleles of four polymorphisms c5-155G/C, c5-147G/del,  
c5-144T/C and c5-142T/A that was completely identical to the homologous 
region in the CGB8 gene exhibiting no genetic variation at these positions 
(Figure 7B). This DNA stretch (including c5-155C/c5-147del/c5-144C/c5-
142A) probably originates from the CGB8 gene via a meiotic gene conversion 
event between the two promoter regions. The haplotypes carrying this CGB8-
specific DNA sequence (H1, H2, H10, H11) formed a separate clade on the 
haplotype network of the CGB5 5’ upstream region (Figure 7B). It was 
speculated that in some pregnancies with impaired trophoblast growth (due to 
genetic, thrombophilic, immunological or other reasons), the placenta with the 
most efficient CGB5 promoter haplotype (originating from and identical to the 
efficient CGB8) may have a better capacity for extra hCG production that may 
eventually rescue the threatened fetuses.  
Concordantly, the minor allele frequency of the four CGB5 SNPs was higher 
in fertile women (12.05–13.08%) compared to RM group (7.10–7.92%) in 
Estonian and Finnish populations combined and the association testing with the 
occurrence of RM identified a modest but significant protective effect for these 
SNPs (P < 0.025; OR = 0.54–0.58; Table 3 in Ref. IV). The results were 
successfully replicated in a meta-analysis study across the Estonian, Finnish and 
an independent RM case-control sample set from Denmark (RM cases with 
three or more consecutive miscarriages, n = 450; fertile women with at least two 
normal pregnancies and no miscarriages, n = 119) (P = 0.021; Table 2 in 
Ref. V). A strong protective effect against RM was also observed for a genic 
SNP c5EF1038 in CGB5 intron 2 (Cochran-Armitage trend test P < 0.007; 
OR = 0.53 [95% CI 0.32–0.85]) with the frequency of 14.36% in fertile women 
compared to 8.15% in the RM group of Estonian and Finnish combined sample 
(Table 3 in Ref. IV). However, the allele frequency of this polymorphism did 
not differ between the RM cases and controls in the Danish replication sample 
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(MAF, 7.14% versus 7.42%, respectively; Cochran-Armitage trend test P = 0.52) 
and was not associated with RM (Ref. V). 
 
3.2.1.4. Rare non-synonymous mutations in CGB5 and CGB8  
In addition to the spectrum of SNPs described in the CGB5 and CGB8 genes, 
four rare mutations leading to non-synonymous amino acid changes in the 
hCGβ protein were identified: CGB5 p.Val56Leu in a single Finnish RM 
patient, p.Arg8Trp and p.Pro73Arg substitutions in the CGB8 gene of single 
Estonian patients, and CGB8 p.Val29Ile in one Finnish patient, two Estonian 
patients and seven Estonian fertile women (positions in the mature hCGβ 
protein; Table 1 in Ref. III). The three missense mutations (CGB5 p.Val56Leu, 
CGB8 p.Arg8Trp and p.Pro73Arg) exclusively present among the cases were 
speculated to have impact on the production of hCG β-subunit protein in 
placenta and thus re-occurrence of miscarriages. 
 
3.2.2. Structural and functional impact of non-synonymous 
mutations in CGB5 and CGB8 (Ref. V) 
Rationale of the study: 
In spite of the functional relevance of hCGβ in the establishment of pregnancy, 
the studies on genetic variation of the CGB genes and hCGβ protein has been 
challenging due to a high sequence similarity between the gene copies as well 
as the hCGβ proteins coded by these genes (98–100%) (Ref. II, III). Thus, only 
one naturally occurring variant of hCG (CGB5 p.Val79Met) has been 
functionally characterized leading to inefficient hCG assembly in vitro (Miller-
Lindholm et al. 1999). To assess the impact of the novel missense mutations 
identified by our screening study exclusively among the Estonian and Finnish 
RM cases (p.Arg8Trp, p.Val56Leu and p.Pro73Arg; Ref. IV), I conducted 
series of experiments addressing the structural and functional features of 
recombinant hCGβ proteins carrying these amino acid changes (performed in 
I.T. Huhtaniemi’s lab, Imperial College London, UK; Ref. VI).  
 
3.2.2.1. Prevalence and positional context  
of mutations p.Arg8Trp, p.Val56Leu and p.Pro73Arg 
The prevalence of the rare mutations p.Arg8Trp, p.Val56Leu and p.Pro73Arg 
was estimated in a combined sample set of the discovery subjects from Estonia 
and Finland (described in Ref. IV) and replication sample from Denmark 
(described in Ref. V) (in total, 655 RM cases and 431 fertile female controls). 
Two of the studied substitutions CGB5 p.Val56Leu (rs72556325, g.1178G>C; 
located in exon 3, Figure 8A) and CGB8 p.Arg8Trp (rs72556341, g.806C>T; 
exon 2; Figure 8A) were each identified in a single heterozygous RM patient, 
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whereas the CGB8 p.Pro73Arg mutation (rs72556345, g.1237C>G; exon 3; 
Figure 8A) was identified with a similar carrier frequency (0.46%) among RM 
(3/655) and control (2/431) individuals in the full screened Northern-European 
sample set (Estonian, Finnish, Danish, n = 1086) (Table 2 in Ref. VI). 
All three hCGβ missense mutations under study are located immediately 
next to disulfide bond forming cysteins (Cys9, Cys57 and Cys72; Figure 1A in 
Ref. VI). Positions Arg8 and Val56 are involved in the central cystine knot 
structure essential for hCGβ folding and heterodimer assembly, whereas Pro73 
is incorporated in a stable turn of the protein loop 3 that does not directly 
associate with the hCG α-subunit or the human luteinizing hormone/chorionic 
gonadotropin receptor (hLH/CGR) (Figure 8B). Unlike other targeted missense 
mutations, Val56 was found as fully conserved among hCGβ homologs from 
mammals to fishes (Figure 1C in Ref. VI) and was largely buried within the 
hCGα/β heterodimer complex with only 3% exposed to the solvent compared to 
46% in case of the unassembled β-monomer based on Solvent Accessible 
Surface calculations (Figure 2 in Ref. VI). Therefore out of the three mutations 
under study, amino acid substitutions at position Val56 were predicted to have 
most pronounced effect on the hCGβ protein and specifically on the formation 
of the hCGα/β complex. 
 
 
 
 
 
 
 
 
 
Figure 8. Localization of identified non-
synonymous mutations in the CGB5 and 
CGB8 genes (A) and in the structure of 
assembled hCG molecule (B). (A) The 
positions of the mutations in the CGB5 
and CGB8 gene. Gray boxes represent 
exons with the exon number given above. 
Black arrows indicate the direction of gene 
transcription. Cen, centromere; Tel, 
telomere. (B) Three-dimensional (3D) 
structure of the assembled hCG molecule 
based on Protein Data Bank (PDB; 
http://www.pdb.org) entry 1hcn. The 
structure of the hCG -subunit is depicted 
in blue, -subunit in pink and the disulfide 
bonds in yellow. The side chains of amino 
acids Arg8, Val56 and Pro73 in hCG are 
shown in the space-filling representation. 
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3.2.2.2. Structural features and assembly of recombinant hCGβ isoforms  
To study the effect of the rare missense mutations in in vitro experimental 
setup, I constructed four alternative recombinant FLAG-tagged hCGβ variants – 
the wild-type and the hCGβ proteins carrying either p.Arg8Trp, p.Val56Leu or 
p.Pro73Arg mutation. Each FLAG-tagged hCGβ variant was transiently co-
expressed with un-tagged -subunit in the CHO cell line.  
Forty-eight hours after transfection, the media containing the secreted hCGα 
and hCGβ isoforms were collected and subjected to co-immunoprecipitation 
using anti-FLAG antibody for specific precipitation of free FLAG-tagged hCGβ 
monomers and heterodimeric hCGα/β complexes. To study the structure and 
assembly of the expressed isoforms, the retrieved molecules were run on SDS-
PAGE and detected by Western blot using either the anti-FLAG antibody which 
probed for both hCG monomers and assembled / heterodimers (Figure 
9A,C), or via antiserum against hCG -subunit which specifically visualizes 
assembled heterodimer hormone only (Figure 9B). Either non-reducing (Figure 
9A,B) or reducing (Figure 9C) SDS-PAGE conditions were used based on 
either absence or presence of 2-mercaptoethanol and heat denaturation, 
respectively. 
 
 
Figure 9. Co-immunoprecipitation and Western blot analysis of FLAG-tagged hCGβ 
variants co-expressed with hCGα in CHO cells. FLAG-tagged hCG monomers and 
associated complexes were immunoprecipitated from CHO cell culture media using 
anti-FLAG antibody-conjugated beads and separated by SDS-PAGE under non-
reducing (A,B) or reducing (C) conditions. (A,C) Free and heterodimeric assembled 
FLAG-tagged hCG was detected using anti-FLAG antibody. (B) Heterodimeric hCG 
was specifically visualized using antiserum to hCG -subunit. Bands corresponding to 
the heterodimeric hCG and unassembled hCG monomers are indicated by arrowheads; 
bands corresponding to -subunit specific multimeric complexes that have been shown 
to be secreted from the cells, especially in the presence of mutations that affect the  
-subunit folding pathway (Bedows et al. 1994; Feng et al. 1995; Feng et al. 1996), are 
indicated with a bracket. The data is drawn from the same experiment and it is 
representative of three independent co-immunoprecipitation experiments. Alternative 
/ complex with the hCG conformational isoform caused by the p.Pro73Arg 
mutation is indicated by asterisk (*). WT, wild-type. 
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Under non-reducing conditions, the proportion of the p.Val56Leu β-subunits 
incorporated into α/β heterodimers (~47 kDa) relative to the freely retained  
β-monomers (~34 kDa) was notably reduced compared to the wild-type (Figure 
9A,B) indicating a decreased capability of p.Val56Leu β-subunits to assemble 
into the heterodimer and/or destabilizing the assembled hormone. The effect 
was confirmed by the quantitative immunoassays detecting the assembled intact 
hCG (hCG Human ELISA Kit; Abcam, Cambridge, MA) or total hCGβ 
(hCG+β kit on Roche Elecsys 1010 system; measured in Tartu University 
Hospital, Tartu, Estonia) from the cell culture media. The efficiency of hCG 
assembly (measured as the ratio of assembled hCG to the total hCGβ amount) 
was decreased down to 10% compared to the wild-type hCGβ (= 100%; 
Student’s t test, P = 0.014) (Figure 5 in Ref. V). The results are largely con-
cordant with the in silico positional context analysis predicting the hindrance of 
p.Val56Leu substitution upon the hCG heterodimer formation due to its location 
immediately next to Cys57 in the highly conserved structural feature, the 
cystine knot (Figure 8B). The Cys57 forms the Cys9-Cys57 disulfide bond 
disruption of which has previously been shown to give rise to folding and 
assembly deficient hCGβ protein (Bedows et al. 1994; Mishra et al. 2003).  
The hCG p.Pro73Arg mutant gave rise to approximately equal amounts of 
two alternative hCG isoforms, one corresponding to the molecular weight of 
the wild-type hCG (~34 kDa) and an additional variant with approximately 
2 kDa lower molecular weight (Figure 9A,B). Pro73 is located next to the 
Cys72 that forms one of the six hCGβ disulfide bonds, Cys23-Cys72. It has 
been demonstrated previously that disruption of this bond affects the hCGβ 
folding pathway leading to secretion of an additional isoform lacking the 
Cys23-Cys72 bond and exhibiting a difference of 2 kDa in size on SDS-PAGE 
(Bedows et al. 1993; Bedows et al. 1994). Nevertheless, both isoforms detected 
in this study were assembled into hCG dimer with approximately equal 
efficiency (Figure 9A,B). 
In the case of hCG p.Arg8Trp substitution, no detectable differences in the 
fraction of free hCG or in the assembly of intact hCG compared to the wild-
type variant were revealed (Figure 9). Also, no evidence of the effect of the 
studied three substitutions on the glycosylation pattern of the hCG protein was 
seen based on the SDS-PAGE performed under reducing conditions that cause 
dissociation of hCG dimers and disruption of disulfide bonds. All tested hCG 
variants collapsed into one major (~34 kDa) and one minor (~31 kDa) isoform 
(Figure 9C), previously shown to contain either two or one N-linked oligo-
saccharide chains, respectively (Matzuk et al. 1987). 
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3.2.2.3. Bioactivity of recombinant hCGβ isoforms  
Bioactivity of the hCG hormone can be estimated based on its ability to induce 
cAMP signaling upon binding to the human LH/CG receptor. In order to 
achieve sufficient signaling response, a high concentration of FLAG-tagged 
intact hCG (termed ‘high yield’ hCG) was produced using QMCF technology 
(by Icosagen Cell Factory OÜ; Supplemental data, Text S1 in Ref. VI) (Silla et 
al., 2005). I used the series of diluted cell-conditioned media containing either 
the wild-type or mutant ‘high yield’ hCG adjusted for concentration of hCG 
heterodimer to stimulate HEK293 cell-line stably transfected with the human 
LH/CG receptor (HEK-hLH/CGR) and containing the cAMP-responsive (CRE) 
firefly luciferase reporter gene. After 5–6 h stimulation, the CRE-luciferase 
activity was determined and the EC50 values (± standard deviation, SD) [EC50 is 
defined as the concentration of the hormone required to produce 50% of 
maximal response] were estimated for each hCG isoform.  
Interestingly, although the CGB5 p.Val56Leu substitution leads to inefficient 
assembly and/or instability of the heterodimeric hCG, the in vitro bioactivity 
analysis indicated an increased potency of this isoform. The cAMP response to 
stimulation by the p.Val56Leu heterodimer was significantly more sensitive 
than to wild-type hCG (Figure 10), exhibiting a half-maximal response EC50 of 
2.50 ± 0.81 pg/ml compared to the wild-type hCG EC50 of 11.41 ± 2.32 pg/ml  
(t test P <0.0013). As a consequence, the shortage of the produced hetero-
dimeric hormone (10% compared to wild-type) may be partly or fully compen-
sated for by its increased bioactivity. 
The hCGβ variant carrying the CGB8 p.Pro73Arg mutation did not induce 
differences in the cAMP signaling when compared to the wild-type hCG 
(P = 0.053; Figure 10) despite the appearance of two alternative hCGβ isoforms 
on SDS-PAGE (Figure 9). Importantly, the overall functional characteristics of 
the assembled hCG thus remained comparable to the wild-type pointing to the 
functional neutrality of this mutation. 
The p.Arg8Trp hCGβ isoform represented a fully neutral amino acid 
substitution out of the three addressed in this study as no impact on structural or 
functional characteristics were observed compared to the wild-type hCGβ 
variant. 
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Figure 10. Bioactivity of hCGβ variants measured as hLH/CG receptor mediated cAMP 
signaling response to stimulation with the dosage gradient of heterodimeric wild-type 
(WT) and mutant hCG preparations. Stimulation with wild-type hCGβ or hCGα 
monomers was used as a negative control. The fold response is given as a ratio of CRE 
luciferase activity to unstimulated cells. The data are the mean ±SD of five independent 
experiments. 
 
 
3.3. DNA copy number variants in recurrent  
miscarriage (Ref. VII) 
Rationale of the study: 
Previously published studies addressing the genetic etiology of RM have pri-
marily targeted SNPs producing few confirmed disease risk variants. Although 
the alternative genetic variation class of copy number variants (CNVs) has been 
associated with various complex disorders, it has been largely understudied in 
pregnancy complications. My goal in this study (Ref. VII) was to elucidate the 
role of CNVs in modulating predisposition to RM. 
 
3.3.1. Genome-wide profile of CNVs 
In order to define genome-wide profile of CNVs specific to RM cases or fertile 
controls, screening with Illumina Human370CNV-Quad SNP array was 
undertaken in 70 Estonian subjects including 27 female and 16 male idiopathic 
RM cases with at least three miscarriages before gestational week 22 and 27 
female controls with at least three live births and no miscarriages prior to 
recruitment. On average, 13.3 CNVs were determined per individual among the 
RM cases (in total, n = 43) and 12.6 CNVs/individual in fertile controls 
(n = 27). Identified CNVs clustered into 423 non-overlapping discrete Copy 
Number Variable Regions (CNVRs) (Supplemental Table S3 in Ref. VII) that 
were uniformly distributed across the genome (Figure 11). 
45 
 
 
Figure 11. Circos plots with frequency and distribution of deletion and duplication 
CNVRs across the genome among the Estonian discovery cases (n = 43) and controls 
(n = 27). The length of the bars (Y-axis) in the histogram represents the number of 
carriers of a CNV at the genomic locus, whereas the width correlates with the size of the 
CNVR. Single occurrence CNVs are highlighted in the yellow background. The number 
of carriers for outlier CNVRs of high frequency (>8 carriers in a study group) are 
indicated next to respective bars. 
 
In accordance with the known heterogeneity in the etiology of RM (Rai and 
Regan 2006), an individual-specific increased risk of RM was inferred for a 
subset of patients using case-by-case CNV profile analysis. Five outlier cases 
(12% of RM subjects studied) were observed with (i) a 5-fold excess 
cumulative burden of all CNVs (up to 6.1 Mb per genome) mostly comprising 
of long (>100 kb) deletions (Figure 12A) or (ii) accumulation of long deletions 
with very high gene count (up to 189 genes per individual compared to only a 
median of 8.3 genes among the fertile controls) (Figure 12B). The list of 
rearranged genes in the outlier cases with the largest cumulative burden of all 
CNVs (n = 2; Figure 12A) involved several known or potential candidate genes 
for RM and pregnancy success, such as C4A, C4B, IGF2 or Immunoglobulin 
heavy chain (IGH) gene cluster that may contribute to the increased chances of 
miscarriages among these patients. 
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Figure 12. Genomic burden of all CNVs and the subset of long (≥100 kb) deletions in 
the Estonian discovery phase sample set. (A) Cumulative length of all deletions and 
duplications per individual in RM patients (n = 43) and fertile controls (n = 27). The 
outlier cases with increased cumulative burden of all CNVs are indicated with asterisk. 
(B) Cumulative length of long deletions and the number of disrupted genes per 
individual in the discovery phase cases and controls. The outlier cases with increased 
number of genes disrupted by long deletions are indicated with asterisk. Female and 
male patients with identical number-codes represent RM couples (e.g. RM-F45 and 
RM-M45). FFC, fertile female control; RM-F, female RM patient; RM-M, male RM 
patient. 
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3.3.2. Functional enrichment of genes disrupted by CNVs  
To define the functional impact of the discovered CNVs and identify biological 
pathways significantly affected by the CNVs, functional enrichment analysis 
was performed for the list of all disrupted genes in either RM cases (1459 
genes) or fertile female controls (553 genes) using g:Profiler software (Reimand 
et al. 2011). Among the cases, the results highlighted the specific impact of 
CNVs on the processes of immunomodulatory function at the feto-maternal 
interface related to maternal rejection of the semi-allogeneic fetus expressing 
paternally inherited alloantigens. Functional categories such as ‘Innate 
immunity signaling’ (REAC: 168249; 11.0% of genes disrupted by CNVs, 
multiple testing corrected P = 3.57 × 10–3), ‘Fc gamma receptors interact with 
antigen-bound IgG’ (REAC: 199161; 26.3% disrupted genes, P = 9.97 × 10–6) 
and ‘Complement cascade’ (REAC: 166658; 15.6% disrupted genes, 
P = 1.93 × 10–4) (Table 1 in Ref. VII) were significantly and specifically 
overrepresented in RM case sample. None of the immunomodulatory pathways 
were significantly affected by CNVs among the controls and only processes 
associated with general cellular function were identified (Table 1 in Ref. VII). 
 
3.3.3. Identification of novel common CNV regions  
conferring risk to recurrent miscarriage 
In search for novel common CNV regions that may independently modulate the 
predisposition to RM, I performed an experimental analysis of prioritized 
discrete CNV regions and conducted association study in two North European 
populations. 
 
3.3.3.1. Prioritized CNVRs affecting RM in Estonia and Denmark  
Nine discrete common CNV regions were selected from the whole genome SNP 
array genotyping data (Supplemental Table S4 in Ref. VII) for subsequent 
experimental testing in the Estonian discovery sample set (n = 70) using 
TaqMan qPCR. The selection included CNVRs that were (i) present in >1 
individual, (ii) found only among RM patients or overrepresented in RM 
patients with OR ≥1.5 and (iii) intersected with or located in the proximity (up 
to approximately 200 kb) of biological candidate genes with a potential impact 
on the course of pregnancy based on previously published literature. Three 
CNVRs with precise TaqMan copy number typing assays were tested in the full 
Estonian sample set: CNV regions of IGKV (Immunoglobulin kappa variable 
cluster at 2p11.2), DKK2 (Dickkopf 2 homolog, at 4q25), and PDZD2:GOLPH3 
(PDZ domain containing 2; Golgi phosphoprotein 3 at 5p13.3)). 
The PDZD2:GOLPH3 duplication exhibited he strongest effect (OR = 7.28) 
with a higher prevalence of duplication carriers among the Estonian RM cases 
compared to fertile controls (9/119, 7.6% versus 1/90, 1.1%, respectively) 
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(Supplemental Table S7 in Ref. VII). However, analysis of the Danish 
replication sample (in total, 439 RM patients with ≥2 consecutive miscarriages, 
115 multiparous fertile female controls) identified increased prevalence of the 
duplication only among female patients who exhibited carrier frequency 
comparable to Estonian female cases (6.6% and 7.5%, respectively) (Figure 13; 
Supplemental Table S8 in Ref. VII). Meta-analysis combining the results of the 
Estonian and Danish female patient-control samples (in total, cases n = 309, 
controls n = 205) confirmed the association of the PDZD2:GOLPH3 CNV with 
an increased maternal risk of RM (OR = 4.82, P = 0.012). (Table 2 in Ref. VII). 
Concordantly, high risk of RM associated with the duplication was detected 
when the Estonian RM women were independently tested against female 
controls of Estonian population cohort from the Estonian Genome Center, Uni-
versity of Tartu (EGCUT) (n = 496; prevalence 1.0%; OR = 7.96, P = 7.9 × 10–4) 
(Figure 13). 
The IGKV and DKK2 CNVs with small differences in carrier frequencies in 
the full Estonian case-control sample (Supplemental Table S7 in Ref. VII) 
likely represent benign common copy number variation with no major effect on 
the RM phenotype in our study.  
 
 
Figure 13. Copy number distribution and carrier frequency of the PDZD2:GOLPH3 
duplication at 5p13.3 among female study subjects. CNV carriers have 3 to 4 copies of 
the duplication per genome in Estonia and 3 to >4 copies per genome in Denmark. Dup, 
duplication; EGCUT, Estonian population cohort from Estonian Biobank, Estonian 
Genome Center, University of Tartu. 
 
3.3.3.2. Genomic context and  
fine-mapping of the PDZD2:GOLPH3 duplication  
To define the range and nature of the PDZD2:GOLPH3 duplication (occurring 
in up to >4 diploid copies) at 5p13.3 predisposing to RM, I set forward to fine-
map the duplication breakpoints by integrating experimental (EvaGreen qPCR, 
PCR, sequencing) and bioinformatic approaches (including screening for 
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repetitive elements with RepeatMasker, http://www.repeatmasker.org/; and non-
B DNA sequence motifs with Non-B DNA Motifs Search Tool, 
http://nonb.abcc.ncifcrf.gov/apps/nBMST/default/). The CNVR was estimated 
as 61.6 kb in length (positioned Chr5: 32106204 – 32167777), whereas the 
duplication breakpoints were located within DNA repetitive elements in the 
introns of PDZD2 and GOLPH3 genes that are transcribed in the opposite 
direction (Figure 14A,B). Application of duplication breakpoint junction-
specific PCR (BP-PCR, Figure 14B) identified an identical recurrent tandem 
duplication event in all CNV carriers of this study. It was hypothesized that the 
PDZD2:GOLPH3 duplication occurred via repeat-mediated rearrangement 
mechanisms other than non-allelic homologous recombination. Although the 
PDZD2:GOLPH3 rearrangement does not involve entire coding regions of the 
genes, the modifications in the local genomic context may nevertheless lead to 
impaired function of the involved or neighboring genes as reported previously 
(Henrichsen et al. 2009a; Henrichsen et al. 2009b). 
 
3.3.3.3. Expression profile of PDZD2 and GOLPH3  
Neither PDZD2 nor GOLPH3 has been associated with pregnancy success 
previously and have mostly gained attention due to their role in tumorigenesis 
(Tam et al. 2006; Scott et al. 2009). Thus little is known on the tissue 
expression profile of these genes.  
In order to identify the major sites of expression, I performed an expression 
profiling analysis using human tissue cDNA panels (Human MTC panels I and 
II; BD Biosciences Clontech, CA) and TaqMan qPCR assays specific to the 
transcripts of PDZD2 and GOLPH3. I detected the most prominent expression 
for both genes in the placenta that exceeded other sites of highest expression 
twofold for GOLPH3 (average expression relative to reference HPRT,  
2.99 ± 0.06 SEM in placenta versus 1.50 ± 0.05 in prostate) or fourfold for 
PDZD2 (relative expression 1.33 ± 0.05 in the placenta versus 0.36 ± 0.01 in 
heart) (Figure 14C). Interestingly, ovary was also included in the top three sites 
of expression for both GOLPH3 and PDZD2 (1.13 ± 0.02 and 0.34 ± 0.0, 
respectively) and thus highlighting the functional relevance of these genes in 
reproductive organs and specifically in the placenta. 
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Figure 14. Fine-mapping of the PDZD2:GOLPH3 duplication CNV at 5p13.13 and 
expression profiling of the PDZD2 and GOLPH3 genes. (A) Genomic context of 5p13.3 
involving PDZD2 and GOLPH3 genes based on UCSC database (hg19; 
http://genome.ucsc.edu/cgi-bin/hgGateway). The opposite transcription of the PDZD2 
and GOLPH3 genes is indicated with blue and green arrows, respectively. DGV Struc 
Var, structural variation data from the Database of Genomic Variants. (B) Schematic 
representation of the 5p13.3 CNV locus with or without tandem duplication. Experi-
mentally confirmed duplication endpoints are indicated with red arrowheads and dotted 
lines. The breakpoint junction of the tandem duplication is marked with red arrow tail 
and locations of breakpoint junction-specific PCR (BP-PCR) primers are indicated with 
black arrows. In case of tandem duplication, a 555 bp product was amplified and 
subsequently confirmed by resequencing. Ex, exon. (C) Gene expression profile of the 
PDZD2 and GOLPH3 genes in the human cDNA tissue panels. Expression level is 
given relative to the reference gene HPRT and as average of three amplification 
reactions ± SEM. Gene expression levels in placenta and ovary are highlighted with 
colored bars. 
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4. DISCUSSION 
4.1. Nature and impact of fine-scale genetic variation  
of the LHB/CGB region in RM 
The genes encoding the hormone-specific hCGβ subunit are one of the most 
attractive targets in addressing fine-scale genetic etiology of early pregnancy 
loss as the requirement of the ‘pregnancy hormone’ hCG for the establishment 
and maintenance of pregnancy is absolute. The genomic landscape of the 
LHB/CGB gene cluster in humans described in this thesis has likely been 
shaped by a complex interplay between active genome dynamics and balancing 
act of functional constraints maintaining the effectiveness of the LHβ/CGβ 
genes. Extensive DNA sequence identity between DNA segments, density of 
Alu elements, formation of DNA hairpin conformation and presence of 
recombination warm/hot spots in the LHB/CGB region are rich substrates for 
increasing genome instability and gene conversion activity (Chen et al. 2007; 
Chuzhanova et al. 2009). As a result of the active genome dynamics, complex 
evolutionary rearrangements involving multiple duplication events have given 
rise to a varying number of CGB genes among primates with six gene copies in 
humans and up to even 50 copies predicted for gorilla (Dumas et al. 2007; 
Hallast et al. 2008). The abundant duplicated segments have been further 
shaped by the directional interlocus gene conversion which is a common 
phenomenon in the duplicated parts of the human genome and has introduced 
diversity at the edges of the gene cluster on one hand and on the other hand, has 
homogenized the duplicated genes maintaining the recombinogenic potential of 
the region (Dumont and Eichler 2013; Fawcett and Innan 2013).  
It is noteworthy that in spite of the genomic instability and gene conversion 
activity spreading polymorphisms between gene copies but also introducing de 
novo mutations (Hicks et al. 2010; Dumont and Eichler 2013), no gene variants 
of substantial effect on pregnancy success have been identified in hCGβ coding 
genes so far. The data suggest an accompanying action of selection forces in 
order to maintain the functional efficacy of the genes and concurrently, 
balancing selection acting on the promoter region of CGB8 and driving the most 
effective transcription among the CGB genes was reported in this thesis (Ref. 
IV). Furthermore, the polymorphism screening of the two most actively 
transcribed hCGβ-coding genes CGB5 and CGB8 and subsequent association 
testing noted the lack of risk alleles associated with RM disease in Northern 
European populations. Only a protective effect against RM was observed for the 
motif of four regulatory polymorphisms in the CGB5 gene likely transferred 
from the respective region of CGB8 genes via non-reciprocal gene conversion 
event (Ref. IV and V). Similar intricate action of gene conversion and func-
tional constraints in modifying the local genomic context has been observed for 
other complex genomic regions associated with pregnancy course, including 
growth hormone/ somatomammotropin (Sedman et al. 2008), killer 
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immunoglobulin-like receptor (Yawata et al. 2006; Graef et al. 2009), 
pregnancy-specific glycoprotein (McLellan et al. 2005; Dumont and Eichler 
2013) gene families and MHC class II region (von Salome et al. 2007).  
Further evidence of the functional constraints acting on hCGβ genes due to 
their irreplaceable role in human pregnancy is suggested by the lack of non-
synonymous mutations conferring large functional effect within the genes. Out 
of the three missense mutations identified in the major hCGβ genes, CGB5 and 
CGB8, and addressed in this thesis (CGB5 p.Val56Leu, CGB8 p.Arg8Trp and 
p.Pro73Arg), only the p.Val56Leu substitution was initially found to hinder the 
assembly of the heterodimeric hormone (Ref. VI). However, the simultaneous 
5-fold increase in potency partly or fully compensated for the low proportion of 
the assembled heterodimer (10% compared to wild-type) restoring the overall 
functional effect. Although inefficient hCG assembly has also been shown for 
the only naturally occurring variant of hCGβ (CGB5 p.Val79Met) characterized 
in vitro (Miller-Lindholm et al. 1999), no clinical information was available on 
the mutation carriers and the substitution was completely absent in a subsequent 
study of over 500 DNA samples from five European populations (Jiang et al. 
2004). Only few other missense mutations have been identified in populations 
world-wide in the CGB5 (p.Arg6Gln in Han Chinese; p.Asp117Ala in African 
Mandekalu; Ref. III) and CGB8 genes (p.Val29Ile in Estonia and Finland; Ref. 
IV) with the carrier frequency of <10% in all cases but with no clinical 
information available for most of the mutation carriers. Furthermore, no 
individuals homozygous for any hCGβ mutations have been reported so far, 
which may indicate either an insufficient sample size in the conducted studies 
or that such genotypes result in complete pregnancy failure.  
The lack of risk variants of substantial effect in the major hCGβ genes raises 
the question of missing genetic factors responsible for the large interindividual 
variation of hCGβ genes in gene expression during pregnancy and dysregulated 
expression in pregnancy disorders (Ref. II) (Miller-Lindholm et al. 1997; Rull 
and Laan 2005). It has been speculated whether the pathologically low hCG 
levels are indeed the primary cause of pregnancy loss or a secondary 
phenomenon resulting from inadequate placental maturation due to alternative 
risk factors (Larsen et al. 2013). Considering the genetic heterogeneity of the 
RM phenotype, it is feasible that both scenarios are relevant and the 
predisposing genetic profile of hCGβ genes that is likely subject to constant 
dynamic changes is responsible for only a subset of RM cases exhibiting 
decreased expression levels of hCGβ transcripts. 
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4.2. Genome-wide effect of CNVs in RM 
4.2.1. Genomic CNV burden as risk factor for RM 
The application of genome-wide CNV screening and analysis methods has 
enabled to compile a parental profile of CNVs predisposing to recurrent 
miscarriage in this thesis. A case-by-case analysis identified a subgroup of RM 
patients (in total, 5 out of 43; 12%) exhibiting accumulation of several long 
(>100 kb) deletions or long deletions with very high gene count (Figure 12; 
Ref. VII) potentially responsible for the manifestation of the disease in these 
individuals. An enrichment of large (cutoff 100 kb or larger) structural variants 
have been commonly associated with an increased risk of complex diseases 
previously, including neurodevelopmental disorders, longevity or severe obesity 
(Bochukova et al. 2010; Girirajan et al. 2011a; Kuningas et al. 2011). 
Furthermore, higher genome-wide prevalence of gene-rich long deletions has 
been reported for individuals affected by autism spectrum disorders and 
schizophrenia (Consortium 2008; Pinto et al. 2010; Griswold et al. 2012).  
The deleterious nature of large rearrangements and specifically long 
deletions in gene-rich regions likely originates from increased chances of 
affecting loci relevant to pregnancy success. Gene content analysis of CNVs 
identified among RM cases with the largest overall genomic burden of 
rearrangements highlighted some potential dosage sensitive candidate genes, 
including C4A and C4B previously implicated in RM (Laitinen et al. 1991). The 
findings indicate that large cumulative burden of CNVs or gene-rich deletions 
could be regarded as an independent risk factor of RM, however the statistical 
significance of these findings remains to be tested further. 
 
4.2.2. Genetic variability of immunoregulatory pathways  
as risk factor for RM 
Adequate bi-directional communication at the feto-maternal interface and 
immunologic recognition of pregnancy have been proposed as of utmost 
importance for implantation and maintenance of early pregnancy. Fetal rejection 
due to either auto- or alloimmune factors is a major contributor in RM disease 
(reviewed in (Pandey et al. 2005; Baek et al. 2007)) and a number of candidate 
loci related to placental immune function have been implicated in RM 
independently or cumulatively, such as KIR and HLA gene families (Hviid et al. 
2004; Hiby et al. 2008; Aruna et al. 2011). Similar to thrombophilic genetic 
factors, it has been suggested that only failure of several mechanisms or 
systematic deviations in pathways would lead to the occurrence of RM due to a 
likely redundancy in the immune function at the feto-maternal interface 
protecting against the fetal rejection (Jivraj et al. 2006; Larsen et al. 2013).  
Multiple pieces of evidence indicate the contribution of structural variants in 
modifying the profile of genes related to immune function in pregnancy. In this 
thesis, significant enrichment of genes from immunomodulatory pathways were 
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observed within the rearranged loci of RM patients with half of the pathways 
specific to cases and not affected among controls, including complement 
cascade and innate immunity related processes (Table 3 in Ref. VII). The role of 
CNVs in promoting common genetic variability of immune system loci has 
previously been reported for human immunoglobulin heavy chain variable 
(IGHV) (Watson et al. 2013) and constant (IGHC) loci (Lefranc et al. 1991), 
beta-defensins (Hollox et al. 2008) and duplicate KIR genes (Jiang et al. 2012) 
indicating the potential susceptibility of these regions also to disease risk-
conferring rearrangements. Furthermore, it has been shown that CNVs modulate 
and define the profile of presented antigens in the graft-versus-host disease, the 
condition of compromised immunity similar to fetal rejection in pregnancy 
(Guleria and Sayegh 2007; McCarroll et al. 2009). The accumulating data 
support the notion that CNVs may considerably affect the function of 
alloimmune factors and increase the risk of early miscarriages originating from 
feto-maternal genetic mismatch. 
 
 
4.3. Global genomic analysis as the source  
of novel biomarkers 
Hypothesis-free genome-wide approach in studying disease susceptibility is a 
powerful tool not only in uncovering novel pathways but also facilitating 
identification of novel genes and genetic variants increasing the risk of disease. 
Genome-wide studies targeting CNVs have been the source of numerous novel 
dosage sensitive candidate genes for complex diseases but also for recurrent 
miscarriage as reported previously by (Rajcan-Separovic et al. 2010). Aber-
rations of the imprinted genes TIMP2 and CTNNA3 in the placenta were 
implicated in increased risk of pregnancy loss and thus represent the risk factors 
specific to the fetus/offspring. Alternatively, screening of parental genomes may 
provide data on the genetic susceptibility of either or both parents to the 
occurrence of repetitive miscarriages.  
A strong maternal risk of RM was identified for the 61.6 kb multicopy 
duplication of PDZD2 and GOLPH3 genes (chromosome position 5p13.3) in 
this thesis among women from Estonia and Denmark (meta-analysis, OR = 4.82, 
P = 0.012; Ref. VII). Interestingly, in addition to being transcribed in the female 
reproductive organ ovary, the highest expression of both of the involved genes 
was identified in the placenta (Figure 14C; Ref. VII). It was speculated that the 
increased predisposition to RM among the female duplication carriers may be 
attributed to the joint effect in maternal reproductive tissues and in the placental 
tissue carrying a maternally inherited duplication CNV. 
The relevance of the PDZD2:GOLPH3 duplication as a novel biomarker in 
pregnancy disorders can be estimated based on two findings. Firstly, the 
PDZD2:GOLPH3 duplication CNV may represent a pleiotropic risk factor of 
pregnancy disorders as its risk-conferring effect is not restricted to RM. A 
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recent CNV association study identified the duplication as a potential risk factor 
in women affected by pre-eclampsia – a severe late pregnancy disorder 
attributed to placental dysfunction (Zhao et al. 2013). The overlapping causality 
of RM and pre-eclampsia (Li and Huang 2009; Baig et al. 2013) but also early 
pregnancy loss and fetal growth restriction (Ganguly et al. 2007) has been 
acknowledged previously. 
Secondly, the PDZD2 and GOLPH3 genes affected by the 5p13.3 
duplication CNV are novel candidate genes in the context of early pregnancy 
maintenance and the associated pathways have not been directly linked to the 
occurrence of early pregnancy loss previously. The function of PDZD2 is 
poorly defined, whereas amplification of GOLPH3, essential for Golgi 
trafficking and maintenance of its structure (Dippold et al. 2009; Wood et al. 
2012), has been reported in various cancers and shown to induce the signaling 
of mechanistic target of rapamycin (mTOR) (Scott et al. 2009; Wang et al. 
2012; Hu et al. 2013). The contribution of mTOR in reproductive function is 
however well established and alterations in mTOR signaling have been linked 
to multiple reproductive disorders in human and mouse, including recurrent 
miscarriage (Roos et al. 2007; Hirota et al. 2011; Vatin et al. 2012). The direct 
functional link between the GOLPH3 amplification and mTOR signaling in 
female reproductive tissues and placenta remains to be experimentally 
confirmed. 
 
 
4.4. Status quo and future perspectives  
in assessing genetic determinants of RM 
As pregnancy loss is the most common pregnancy complication, etiology of 
RM has been addressed by considerable number of studies for several decades 
establishing the multifactorial nature of the disease and the contribution of 
genetic susceptibility. Nevertheless, none of the reported variants have 
unequivocally proven as specific to the RM phenotype, neither prevalent among 
the cases leaving a void in the knowledge on disease heritability factors and also 
highlighting the multifactorial nature of the genetic component itself. 
Adjustments in study designs from the genetic and phenotypic perspective may 
prove beneficial in fine-mapping the genetic determinants of RM (also reviewed 
in Ref. I). 
 
Genetic perspective  
The common attractive expectation in studies of RM has been to identify single 
genetic variants of high effect efficiently applicable in clinical diagnostics. 
However, the accumulating research data indicate that very few genetic variants 
exist conferring high risk to RM likely due to the heterogeneity and redundancy 
of mechanisms in early pregnancy as also demonstrated for the polymorphisms 
in the hCGβ coding genes. It has been proposed that instead of single poly-
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morphisms with independent prevalent effect, several genetic variants may 
cumulatively alter pathways essential for pregnancy maintenance (e.g. 
thrombophilic and pro-inflammatory mutations). Alternatively and feasibly, due 
to the multifactorial nature of RM, each case or family may carry a distinct 
genetic factor responsible for the increased risk of the disease observed among 
siblings (Christiansen et al. 2008; Kolte et al. 2011). 
Although no SNP-based GWAS studies have been performed to identify the 
set of single nucleotide variants associated with RM, the genomic profiling of 
CNVs addressed in this thesis supports the hypothesis of cumulative risk of 
multiple rearrangements involving genes within similar pathways (in this case, 
processes related to immune function). The finding of the common 
PDZD2:GOLPH3 duplication independently increasing the risk of RM among 
women with OR = 4.82 in two populations likely reflects the lack of previous 
studies targeting parental CNV profile in RM. Increasing the sample size may 
identify additional CNVs associated with RM, however the number of common 
causative rearrangements is likely to remain low in accordance with and as 
debated for other common diseases (Craddock 2010). 
In order to improve the current knowledge on the whole spectrum of genetic 
factors leading to RM, the focus of the association studies could be further 
shifted from candidate gene-based analysis to genome-wide studies and 
incorporating data from transcriptomics, proteomics and methylomics that have 
become financially, methodologically and analytically more feasible and may 
prove beneficial in interpretation of large-scale genomic data. 
 
Phenotypic perspective 
In order to increase the power of identifying novel genetic variants of lower 
effect size at the genome-wide level, larger case-control samples and replication 
samples would be needed. However, the varying phenotyping criteria of RM at 
different recruitment centers such as (i) the number of miscarriages and live 
births at recruitment of cases and controls, respectively, (ii) exclusion criteria of 
cases (e.g. testing for mutations in factor V (Leiden) or factor II, prothrombin) 
and/or (iii) selection criteria of study subjects (only women versus couples 
versus placenta) may hinder the pooling of sample collections or skew 
replication results. Also, majority of the studies addressing the genetic compo-
nent of RM have focused on only maternal or fetal/placental contribution and 
few have included both parents (Ref. I). As mother and father contribute equally 
into the offspring’s genetic composition, association studies with couples may 
identify novel risk factors leading to early pregnancy loss. In order to uncover 
novel pleiotropic genetic variants not restricted to RM, parallel analysis of 
various pregnancy disorders may prove informative.  
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SUMMARY AND CONCLUSIONS 
The results of this thesis can be summarized as follows: 
 
Fine-scale genetic determinants of RM based on LHB/CGB gene cluster 
1.  The local genomic landscape of luteinizing hormone/chorionic gonadotropin 
β-subunit coding genes (LHB/CGB) in humans reflects the history of 
complex evolutionary processes involving expansion of repetitive elements 
and multiple rearrangements likely promoted by recombination ‘warm and 
hot spots’. A balancing interplay between gene conversion activity spreading 
polymorphisms between the gene copies and functional constraints 
maintaining the transcription efficiency of the genes shapes the region’s 
genomic context. It is likely that the LHB/CGB region is subject to further 
dynamic changes. 
2.  The most actively transcribed hCGβ genes CGB5 and CGB8 were charac-
terized by the lack of genetic variants increasing the risk of RM in the case-
control sample collections from Estonia, Finland and Denmark. Instead, a 
modest protective effect against RM was observed for a motif of four SNPs 
in the CGB5 upstream region transferred from the CGB8 gene via gene 
conversion event. The balancing selection acting on the upstream region of 
CGB8 likely supports the highest transcription activity observed among the 
hCGβ genes.  
3.  The structural and functional analysis of three non-synonymous mutations in 
the CGB5 and CGB8 genes identified a decreased ratio of hCG heterodimer 
assembly for p.Val56Leu substitution. However, the low amount of formed 
heterodimer was compensated by its increased bioactivity upon binding to 
the LH/CG receptor. As only mutations of mild functional effect are tole-
rated and no homozygous carriers of the studied mutations or additional 
missense mutations with functional effect have been described in CGB5 and 
CGB8, it was concluded that keeping the functional efficiency of the major 
hCGβ genes intact is essential for pregnancy maintenance. 
4.  Accumulating data on the fine-scale genetic variation of RM indicates that 
the contribution of independent variants with large effect sizes is not 
sufficient to explain the genetic heritability of RM and rather combinations 
of genetic factors or variants specific to each family lead to the manifestation 
of the disease. 
 
Global genetic determinants of RM based on CNV profiling 
1.  Genome-wide analysis of copy number variants (CNVs) identified a high 
burden of all CNVs or long (>100 kb) gene-rich deletions in a subset of RM 
cases. It was postulated that increased genomic burden of CNVs and 
specifically long deletions may confer risk to RM due to increased chances 
of affecting genes relevant in early pregnancy establishment and 
maintenance. 
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2.  Functional profiling of all genes affected by CNVs among the RM cases 
detected a significant and specific impact of rearrangements on the pathways 
related to immune function at the feto-maternal interface. The findings 
support the contribution of inadequate maternal immune response to semi-
allogeneic fetus expressing paternal antigens in early pregnancy success. 
3.  Screening of distinct common CNV regions identified a novel genetic pre-
disposition marker among women affected by RM in Estonia and Denmark. 
The multicopy duplication at 5p13.3 involved two genes PDZD2 and 
GOLPH3 with the highest expression in placenta but previously uncharac-
terized in the context of pregnancy maintenance. The PDZD2:GOLPH3 
CNV may potentially represent a novel genetic risk factor not restricted to 
RM. 
4.  Global CNV profiling of parental genomes confirmed the contribution of 
structural variants in shaping the genetic susceptibility to RM and may prove 
as an informative source of novel biomarkers in other pregnancy disorders. 
 
 
Main outcome of the thesis: 
This thesis established the low impact of the fine-scale genetic variation in the 
etiology of RM based on the LHB/CGB gene family and highlighted the 
contribution of distinct common CNVs and global burden of structural variants 
in shaping the genetic predisposition to recurrent early pregnancy loss. 
  
59 
REFERENCES 
Agostinis C, Bulla R, Tisato V, De Seta F, Alberico S, Secchiero P, Zauli G. 2012. 
Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion 
and migration of HTR8 trophoblastic cells. Hum Reprod 27(10): 2941–2947. 
Albanese C, Kay TW, Troccoli NM, Jameson JL. 1991. Novel cyclic adenosine 3',5'-
monophosphate response element in the human chorionic gonadotropin beta-subunit 
gene. Mol Endocrinol 5(5): 693–702. 
Aldred PM, Hollox EJ, Armour JA. 2005. Copy number polymorphism and expression 
level variation of the human alpha-defensin genes DEFA1 and DEFA3. Hum Mol 
Genet 14(14): 2045–2052. 
Aldrich CL, Stephenson MD, Karrison T, Odem RR, Branch DW, Scott JR, Schreiber 
JR, Ober C. 2001. HLA-G genotypes and pregnancy outcome in couples with 
unexplained recurrent miscarriage. Mol Human Reprod 7(12): 1167–1172. 
Alkan C, Kidd JM, Marques-Bonet T, Aksay G, Antonacci F, Hormozdiari F, Kitzman 
JO, Baker C, Malig M, Mutlu O et al. 2009. Personalized copy number and 
segmental duplication maps using next-generation sequencing. Nat Genet 41(10): 
1061–1067. 
Aruna M, Nagaraja T, Andal Bhaskar S, Tarakeswari S, Reddy AG, Thangaraj K, Singh 
L, Reddy BM. 2011. Novel alleles of HLA-DQ and -DR loci show association with 
recurrent miscarriages among South Indian women. Hum Reprod 26(4): 765–774. 
Aruna M, Sudheer PS, Andal S, Tarakeswari S, Reddy AG, Thangaraj K, Singh L, 
Reddy BM. 2010. HLA-G polymorphism patterns show lack of detectable 
association with recurrent spontaneous abortion. Tissue Antigens 76(3): 216–222. 
Ascoli M, Fanelli F, Segaloff DL. 2002. The lutropin/choriogonadotropin receptor, a 
2002 perspective. Endocr Rev 23(2): 141–174. 
Baek KH, Choi BC, Lee JH, Choi HK, Lee SH, Kim JW, Hill JA, Chung HM, Ko JJ, 
Cha KY. 2002. Comparison of gene expression at the feto-maternal interface 
between normal and recurrent pregnancy loss patients. Reprod Fertil Dev 14(3–4): 
235–240. 
Baek KH, Lee EJ, Kim YS. 2007. Recurrent pregnancy loss: the key potential 
mechanisms. Trends Mol Med 13(7): 310–317. 
Baig S, Lim JY, Fernandis AZ, Wenk MR, Kale A, Su LL, Biswas A, Vasoo S, Shui G, 
Choolani M. 2013. Lipidomic analysis of human placental syncytiotrophoblast 
microvesicles in adverse pregnancy outcomes. Placenta 34(5): 436–442. 
Bandelt HJ, Forster P, Rohl A. 1999. Median-joining networks for inferring in-
traspecific phylogenies. Mol Biol Evol 16(1): 37–48. 
Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of 
LD and haplotype maps. Bioinformatics 21(2): 263–265. 
Bedows E, Huth JR, Suganuma N, Bartels CF, Boime I, Ruddon RW. 1993. Disulfide 
bond mutations affect the folding of the human chorionic gonadotropin-beta subunit 
in transfected Chinese hamster ovary cells. J Biol Chem 268(16): 11655–11662. 
Bedows E, Norton SE, Huth JR, Suganuma N, Boime I, Ruddon RW. 1994. Misfolded 
human chorionic gonadotropin beta subunits are secreted from transfected Chinese 
hamster ovary cells. J Biol Chem 269(14): 10574–10580. 
Berger P, Gruschwitz M, Spoettl G, Dirnhofer S, Madersbacher S, Gerth R, Merz WE, 
Plas E, Sampson N. 2007. Human chorionic gonadotropin (hCG) in the male 
reproductive tract. Mol Cell Endocrinol 260–262: 190–196. 
60 
Berglund J, Nevalainen EM, Molin AM, Perloski M, Andre C, Zody MC, Sharpe T, 
Hitte C, Lindblad-Toh K, Lohi H et al. 2012. Novel origins of copy number 
variation in the dog genome. Genome biology 13(8): R73. 
Berndt S, Blacher S, Munaut C, Detilleux J, Perrier d’Hauterive S, Huhtaniemi I, Evain-
Brion D, Noel A, Fournier T, Foidart JM. 2013. Hyperglycosylated human chorionic 
gonadotropin stimulates angiogenesis through TGF-beta receptor activation. 
FASEB J 27(4): 1309–1321. 
Beydoun H, Saftlas AF. 2005. Association of human leucocyte antigen sharing with 
recurrent spontaneous abortions. Tissue Antigens 65(2): 123–135. 
Bo M, Boime I. 1992. Identification of the transcriptionally active genes of the 
chorionic gonadotropin beta gene cluster in vivo. J Biol Chem 267(5): 3179–3184. 
Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K, Saeed S, 
Hamilton-Shield J, Clayton-Smith J, O’Rahilly S et al. 2010. Large, rare chromo-
somal deletions associated with severe early-onset obesity. Nature 463(7281): 666–
670. 
Bombell S, McGuire W. 2008. Cytokine polymorphisms in women with recurrent 
pregnancy loss: meta-analysis. Aust N Z J Obstet Gynaecol 48(2): 147–154. 
Breunis WB, van Mirre E, Bruin M, Geissler J, de Boer M, Peters M, Roos D, de Haas 
M, Koene HR, Kuijpers TW. 2008. Copy number variation of the activating 
FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 111(3): 
1029–1038. 
Casarini L, Lispi M, Longobardi S, Milosa F, La Marca A, Tagliasacchi D, Pignatti E, 
Simoni M. 2012. LH and hCG action on the same receptor results in quantitatively 
and qualitatively different intracellular signalling. PloS one 7(10): e46682. 
Cha J, Sun X, Dey SK. 2012. Mechanisms of implantation: strategies for successful 
pregnancy. Nat Med 18(12): 1754–1767. 
Chen JM, Cooper DN, Chuzhanova N, Ferec C, Patrinos GP. 2007. Gene conversion: 
mechanisms, evolution and human disease. Nature reviews Genetics 8(10): 762–
775. 
Choi HK, Choi BC, Lee SH, Kim JW, Cha KY, Baek KH. 2003. Expression of 
angiogenesis- and apoptosis-related genes in chorionic villi derived from recurrent 
pregnancy loss patients. Mol Reprod Dev 66(1): 24–31. 
Christiansen OB, Mathiesen O, Lauritsen JG, Grunnet N. 1990. Idiopathic recurrent 
spontaneous abortion. Evidence of a familial predisposition. Acta Obstet Gynecol 
Scand 69(7–8): 597–601. 
Christiansen OB, Nielsen HS, Kolte AM. 2006. Inflammation and miscarriage. Semin 
Fetal Neonatal Med 11(5): 302–308. 
Christiansen OB, Steffensen R, Nielsen HS, Varming K. 2008. Multifactorial etiology 
of recurrent miscarriage and its scientific and clinical implications. Gynecol Obstet 
Invest 66(4): 257–267. 
Chuzhanova N, Chen JM, Bacolla A, Patrinos GP, Ferec C, Wells RD, Cooper DN. 
2009. Gene conversion causing human inherited disease: evidence for involvement 
of non-B-DNA-forming sequences and recombination-promoting motifs in DNA 
breakage and repair. Hum Mutat 30(8): 1189–1198. 
Clifton VL, Stark MJ, Osei-Kumah A, Hodyl NA. 2012. Review: The feto-placental 
unit, pregnancy pathology and impact on long term maternal health. Placenta 33 
Suppl: S37–41. 
Cole LA. 2009. hCG and hyperglycosylated hCG in the establishment and evolution of 
hemochorial placentation. J Reprod Immunol 82(2): 112–118. 
61 
Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney MJ. 1999. Hyper-
glycosylated human chorionic gonadotropin (invasive trophoblast antigen) 
immunoassay: A new basis for gestational Down syndrome screening. Clin Chem 
45(12): 2109–2119. 
Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, Aerts J, Andrews TD, 
Barnes C, Campbell P et al. 2010. Origins and functional impact of copy number 
variation in the human genome. Nature 464(7289): 704–712. 
Consortium TIS. 2008. Rare chromosomal deletions and duplications increase risk of 
schizophrenia. Nature 455(7210): 237–241. 
Craddock N Hurles ME Cardin N Pearson RD Plagnol V Robson S Vukcevic D Barnes 
C Conrad DF Giannoulatou E et al. 2010. Genome-wide association study of CNVs 
in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 
464(7289): 713–720. 
Daher S, Shulzhenko N, Morgun A, Mattar R, Rampim GF, Camano L, DeLima MG. 
2003. Associations between cytokine gene polymorphisms and recurrent pregnancy 
loss. J Reprod Immunol 58(1): 69–77. 
Diplas AI, Lambertini L, Lee MJ, Sperling R, Lee YL, Wetmur J, Chen J. 2009. 
Differential expression of imprinted genes in normal and IUGR human placentas. 
Epigenetics: official journal of the DNA Methylation Society 4(4): 235–240. 
Dippold HC, Ng MM, Farber-Katz SE, Lee SK, Kerr ML, Peterman MC, Sim R, 
Wiharto PA, Galbraith KA, Madhavarapu S et al. 2009. GOLPH3 bridges 
phosphatidylinositol-4- phosphate and actomyosin to stretch and shape the Golgi to 
promote budding. Cell 139(2): 337–351. 
Dirnhofer S, Hermann M, Hittmair A, Hoermann R, Kapelari K, Berger P. 1996. 
Expression of the human chorionic gonadotropin-beta gene cluster in human 
pituitaries and alternate use of exon 1. J Clin Endocrinol Metab 81(12): 4212–4217. 
Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K. 1997. Fetal carriers of 
the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J 
Obstet Gynecol 177(2): 402–405. 
Dumas L, Kim YH, Karimpour-Fard A, Cox M, Hopkins J, Pollack JR, Sikela JM. 
2007. Gene copy number variation spanning 60 million years of human and primate 
evolution. Genome Res 17(9): 1266–1277. 
Dumont BL, Eichler EE. 2013. Signals of historical interlocus gene conversion in 
human segmental duplications. PloS one 8(10): e75949. 
Elliott MM, Kardana A, Lustbader JW, Cole LA. 1997. Carbohydrate and peptide 
structure of the alpha- and beta-subunits of human chorionic gonadotropin from 
normal and aberrant pregnancy and choriocarcinoma. Endocrine 7(1): 15–32. 
Emerson JJ, Cardoso-Moreira M, Borevitz JO, Long M. 2008. Natural selection shapes 
genome-wide patterns of copy-number polymorphism in Drosophila melanogaster. 
Science 320(5883): 1629–1631. 
Enders AC, Carter AM. 2004. What can comparative studies of placental structure tell 
us? – A review. Placenta 25 Suppl A: S3–9. 
Erlebacher A, Zhang D, Parlow AF, Glimcher LH. 2004. Ovarian insufficiency and 
early pregnancy loss induced by activation of the innate immune system. J Clin 
Invest 114(1): 39–48. 
Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, Kamesh L, Heward JM, 
Gough SC, de Smith A, Blakemore AI et al. 2007. FCGR3B copy number variation 
is associated with susceptibility to systemic, but not organ-specific, autoimmunity. 
Nat Genet 39(6): 721–723. 
16
62 
Faridi RM, Agrawal S. 2011. Killer immunoglobulin-like receptors (KIRs) and HLA-C 
allorecognition patterns implicative of dominant activation of natural killer cells 
contribute to recurrent miscarriages. Hum Reprod 26(2): 491–497. 
Fawcett JA, Innan H. 2013. The role of gene conversion in preserving rearrangement 
hotspots in the human genome. Trends Genet 29(10): 561–568. 
Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL, 
Reinisch W, Teml A, Schwab M, Lichter P et al. 2006. A chromosome 8 gene-
cluster polymorphism with low human beta-defensin 2 gene copy number 
predisposes to Crohn disease of the colon. Am J Hum Genet 79(3): 439-448. 
Feng W, Bedows E, Norton SE, Ruddon RW. 1996. Novel covalent chaperone com-
plexes associated with human chorionic gonadotropin beta subunit folding 
intermediates. J Biol Chem 271(31): 18543–18548. 
Feng W, Matzuk MM, Mountjoy K, Bedows E, Ruddon RW, Boime I. 1995. The 
asparagine-linked oligosaccharides of the human chorionic gonadotropin beta 
subunit facilitate correct disulfide bond pairing. J Biol Chem 270(20): 11851–11859. 
Ganguly A, McKnight RA, Raychaudhuri S, Shin BC, Ma Z, Moley K, Devaskar SU. 
2007. Glucose transporter isoform-3 mutations cause early pregnancy loss and fetal 
growth restriction. American journal of physiology Endocrinology and metabolism 
292(5): E1241–1255. 
Ghosh D, Ezashi T, Ostrowski MC, Roberts RM. 2003. A central role for Ets-2 in the 
transcriptional regulation and cyclic adenosine 5'-monophosphate responsiveness of 
the human chorionic gonadotropin-beta subunit gene. Mol Endocrinol 17(1): 11–26. 
Giovangrandi Y, Parfait B, Asheuer M, Olivi M, Lidereau R, Vidaud M, Bieche I. 2001. 
Analysis of the human CGB/LHB gene cluster in breast tumors by real-time 
quantitative RT-PCR assays. Cancer Lett 168(1): 93–100. 
Girirajan S, Brkanac Z, Coe BP, Baker C, Vives L, Vu TH, Shafer N, Bernier R, 
Ferrero GB, Silengo M et al. 2011a. Relative burden of large CNVs on a range of 
neurodevelopmental phenotypes. PLoS Genet 7(11): e1002334. 
Girirajan S, Campbell CD, Eichler EE. 2011b. Human copy number variation and 
complex genetic disease. Annu Rev Genet 45: 203–226. 
Girirajan S, Rosenfeld JA, Coe BP, Parikh S, Friedman N, Goldstein A, Filipink RA, 
McConnell JS, Angle B, Meschino WS et al. 2012. Phenotypic heterogeneity of 
genomic disorders and rare copy-number variants. New Engl J Med 367(14): 1321–
1331. 
Girirajan S, Rosenfeld JA, Cooper GM, Antonacci F, Siswara P, Itsara A, Vives L, 
Walsh T, McCarthy SE, Baker C et al. 2010. A recurrent 16p12.1 microdeletion 
supports a two-hit model for severe developmental delay. Nat Genet 42(3): 203–
209. 
Glessner JT, Smith AV, Panossian S, Kim CE, Takahashi N, Thomas KA, Wang F, 
Seidler K, Harris TB, Launer LJ et al. 2013. Copy number variations in alternative 
splicing gene networks impact lifespan. PloS one 8(1): e53846. 
Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, 
Freedman BI, Quinones MP, Bamshad MJ et al. 2005. The influence of CCL3L1 
gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 
307(5714): 1434–1440. 
Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, Older Aguilar AM, Gleimer 
M, Hammond JA, Guethlein LA, Bushnell DA et al. 2009. KIR2DS4 is a product of 
gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while 
diminishing avidity for HLA-C. J Exp Med 206(11): 2557–2572. 
63 
Graubert TA, Cahan P, Edwin D, Selzer RR, Richmond TA, Eis PS, Shannon WD, Li 
X, McLeod HL, Cheverud JM et al. 2007. A high-resolution map of segmental DNA 
copy number variation in the mouse genome. PLoS Genet 3(1): e3. 
Grayson BL, Smith ME, Thomas JW, Wang L, Dexheimer P, Jeffrey J, Fain PR, 
Nanduri P, Eisenbarth GS, Aune TM. 2010. Genome-wide analysis of copy number 
variation in type 1 diabetes. PloS one 5(11): e15393. 
Griswold AJ, Ma D, Cukier HN, Nations LD, Schmidt MA, Chung RH, Jaworski JM, 
Salyakina D, Konidari I, Whitehead PL et al. 2012. Evaluation of copy number 
variations reveals novel candidate genes in autism spectrum disorder-associated 
pathways. Hum Mol Genet 21(15): 3513–3523. 
Group TECW. 2010. Europe the continent with the lowest fertility. Hum Reprod Update 
16(6): 590–602. 
Guibourdenche J, Handschuh K, Tsatsaris V, Gerbaud P, Leguy MC, Muller F, Brion 
DE, Fournier T. 2010. Hyperglycosylated hCG is a marker of early human tro-
phoblast invasion. J Clin Endocrinol Metab 95(10): E240–244. 
Guleria I, Sayegh MH. 2007. Maternal acceptance of the fetus: true human tolerance. J 
Immunol 178(6): 3345–3351. 
Guo L, Choufani S, Ferreira J, Smith A, Chitayat D, Shuman C, Uxa R, Keating S, 
Kingdom J, Weksberg R. 2008. Altered gene expression and methylation of the 
human chromosome 11 imprinted region in small for gestational age (SGA) 
placentae. Dev Biol 320(1): 79–91. 
Guryev V, Saar K, Adamovic T, Verheul M, van Heesch SA, Cook S, Pravenec M, 
Aitman T, Jacob H, Shull JD et al. 2008. Distribution and functional impact of DNA 
copy number variation in the rat. Nat Genet 40(5): 538–545. 
Hallast P, Rull K, Laan M. 2007. The evolution and genomic landscape of CGB1 and 
CGB2 genes. Mol Cell Endocrinol 260–262: 2–11. 
Hallast P, Saarela J, Palotie A, Laan M. 2008. High divergence in primate-specific 
duplicated regions: human and chimpanzee chorionic gonadotropin beta genes. BMC 
Evol Biol 8: 195. 
Hanna CW, McFadden DE, Robinson WP. 2013. DNA methylation profiling of 
placental villi from karyotypically normal miscarriage and recurrent miscarriage. Am 
J Pathol 182(6): 2276–2284. 
Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, 
Prus D, Cohen-Daniel L, Arnon TI, Manaster I et al. 2006. Decidual NK cells 
regulate key developmental processes at the human fetal-maternal interface. Nat 
Med 12(9): 1065–1074. 
Harris RA, Ferrari F, Ben-Shachar S, Wang X, Saade G, Van Den Veyver I, Facchinetti 
F, Aagaard-Tillery K. 2011. Genome-wide array-based copy number profiling in 
human placentas from unexplained stillbirths. Prenat Diagn 31(10): 932–944. 
Hawkins SM, Buchold GM, Matzuk MM. 2011. Minireview: The roles of small RNA 
pathways in reproductive medicine. Mol Endocrinol 25(8): 1257–1279. 
Hay DL. 1988. Placental histology and the production of human choriogonadotrophin 
and its subunits in pregnancy. Br J Obstet Gynaecol 95(12): 1268–1275. 
Henrichsen CN, Chaignat E, Reymond A. 2009a. Copy number variants, diseases and 
gene expression. Hum Mol Genet 18(R1): R1–8. 
Henrichsen CN, Vinckenbosch N, Zollner S, Chaignat E, Pradervand S, Schutz F, Ruedi 
M, Kaessmann H, Reymond A. 2009b. Segmental copy number variation shapes 
tissue transcriptomes. Nat Genet 41(4): 424–429. 
64 
Hess AP, Hamilton AE, Talbi S, Dosiou C, Nyegaard M, Nayak N, Genbecev-Krtolica 
O, Mavrogianis P, Ferrer K, Kruessel J et al. 2007. Decidual stromal cell response to 
paracrine signals from the trophoblast: amplification of immune and angiogenic 
modulators. Biol Reprod 76(1): 102–117. 
Hiby SE, Apps R, Sharkey AM, Farrell LE, Gardner L, Mulder A, Claas FH, Walker JJ, 
Redman CW, Morgan L et al. 2010. Maternal activating KIRs protect against human 
reproductive failure mediated by fetal HLA-C2. J Clin Invest 120(11): 4102–4110. 
Hiby SE, Regan L, Lo W, Farrell L, Carrington M, Moffett A. 2008. Association of 
maternal killer-cell immunoglobulin-like receptors and parental HLA-C genotypes 
with recurrent miscarriage. Hum Reprod 23(4): 972–976. 
Hiby SE, Walker JJ, O’Shaughnessy K M, Redman CW, Carrington M, Trowsdale J, 
Moffett A. 2004. Combinations of maternal KIR and fetal HLA-C genes influence 
the risk of preeclampsia and reproductive success. J Exp Med 200(8): 957–965. 
Hicks WM, Kim M, Haber JE. 2010. Increased mutagenesis and unique mutation 
signature associated with mitotic gene conversion. Science 329(5987): 82–85. 
Hirota Y, Cha J, Yoshie M, Daikoku T, Dey SK. 2011. Heightened uterine mammalian 
target of rapamycin complex 1 (mTORC1) signaling provokes preterm birth in mice. 
Proc Natl Acad Sci U S A 108(44): 18073–18078. 
Hoermann R, Spoettl G, Berger P, Mann K. 1995. Immunoreactive human chorionic 
gonadotropin beta core fragment in human pituitary. Exp Clin Endocrinol Diabetes 
103(5): 324–331. 
Hollenberg AN, Pestell RG, Albanese C, Boers ME, Jameson JL. 1994. Multiple 
promoter elements in the human chorionic gonadotropin beta subunit genes 
distinguish their expression from the luteinizing hormone beta gene. Mol Cell 
Endocrinol 106(1–2): 111–119. 
Hollox EJ, Armour JA, Barber JC. 2003. Extensive normal copy number variation of a 
beta-defensin antimicrobial-gene cluster. Am J Hum Genet 73(3): 591–600. 
Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, van de 
Kerkhof PC, Traupe H, de Jongh G, den Heijer M et al. 2008. Psoriasis is associated 
with increased beta-defensin genomic copy number. Nat Genet 40(1): 23–25. 
Holtan SG, Creedon DJ, Haluska P, Markovic SN. 2009. Cancer and pregnancy: 
parallels in growth, invasion, and immune modulation and implications for cancer 
therapeutic agents. Mayo Clin Proc 84(11): 985–1000. 
Hu BS, Hu H, Zhu CY, Gu YL, Li JP. 2013. Overexpression of GOLPH3 is associated 
with poor clinical outcome in gastric cancer. Tumour Biol 34(1): 515–520. 
Huhtaniemi IT, Korenbrot CC, Jaffe RB. 1977. HCG binding and stimulation of 
testosterone biosynthesis in the human fetal testis. J Clin Endocrinol Metab 44(5): 
963–967. 
Huth JR, Mountjoy K, Perini F, Ruddon RW. 1992. Intracellular folding pathway of 
human chorionic gonadotropin beta subunit. J Biol Chem 267(13): 8870–8879. 
Hviid TV, Hylenius S, Lindhard A, Christiansen OB. 2004. Association between human 
leukocyte antigen-G genotype and success of in vitro fertilization and pregnancy 
outcome. Tissue Antigens 64(1): 66–69. 
Jauniaux E, Jurkovic D. 2012. Placenta accreta: pathogenesis of a 20th century 
iatrogenic uterine disease. Placenta 33(4): 244–251. 
Jauniaux E, Poston L, Burton GJ. 2006. Placental-related diseases of pregnancy: 
Involvement of oxidative stress and implications in human evolution. Hum Reprod 
Update 12(6): 747–755. 
65 
Jiang M, Savontaus ML, Simonsen H, Williamson C, Mullenbach R, Gromoll J, 
Terwort N, Alevizaki M, Huhtaniemi I. 2004. Absence of the genetic variant 
Val79Met in human chorionic gonadotropin-beta gene 5 in five European 
populations. Mol Hum Reprod 10(10): 763–766. 
Jiang W, Johnson C, Jayaraman J, Simecek N, Noble J, Moffatt MF, Cookson WO, 
Trowsdale J, Traherne JA. 2012. Copy number variation leads to considerable 
diversity for B but not A haplotypes of the human KIR genes encoding NK cell 
receptors. Genome Res 22(10): 1845–1854. 
Jivraj S, Anstie B, Cheong YC, Fairlie FM, Laird SM, Li TC. 2001. Obstetric and 
neonatal outcome in women with a history of recurrent miscarriage: a cohort study. 
Hum Reprod 16(1): 102–106. 
Jivraj S, Rai R, Underwood J, Regan L. 2006. Genetic thrombophilic mutations among 
couples with recurrent miscarriage. Hum Reprod 21(5): 1161–1165. 
Kajihara T, Uchino S, Suzuki M, Itakura A, Brosens JJ, Ishihara O. 2010. Human 
chorionic gonadotropin confers resistance to oxidative stress-induced apoptosis in 
decidualizing human endometrial stromal cells. Fertil Steril 95(4): 1302–1307. 
Kaufmann P, Black S, Huppertz B. 2003. Endovascular trophoblast invasion: 
implications for the pathogenesis of intrauterine growth retardation and preeclamp-
sia. Biol Reprod 69(1): 1–7. 
Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A. 2003. Human chorionic 
gonadotropin contributes to maternal immunotolerance and endometrial apoptosis 
by regulating Fas-Fas ligand system. J Immunol 171(5): 2305–2313. 
Kehrer-Sawatzki H, Cooper DN. 2007. Structural divergence between the human and 
chimpanzee genomes. Hum Genet 120(6): 759–778. 
Keikkala E, Vuorela P, Laivuori H, Romppanen J, Heinonen S, Stenman UH. 2013. 
First trimester hyperglycosylated human chorionic gonadotrophin in serum – A 
marker of early-onset preeclampsia. Placenta. 
Kim MS, Gu BH, Song S, Choi BC, Cha DH, Baek KH. 2011. ITI-H4, as a biomarker 
in the serum of recurrent pregnancy loss (RPL) patients. Molecular bioSystems 7(5): 
1430–1440. 
Kim YS, Kim MS, Lee SH, Choi BC, Lim JM, Cha KY, Baek KH. 2006. Proteomic 
analysis of recurrent spontaneous abortion: Identification of an inadequately 
expressed set of proteins in human follicular fluid. Proteomics 6(11): 3445–3454. 
Kolte AM, Nielsen HS, Moltke I, Degn B, Pedersen B, Sunde L, Nielsen FC, 
Christiansen OB. 2011. A genome-wide scan in affected sibling pairs with idio-
pathic recurrent miscarriage suggests genetic linkage. Mol Hum Reprod 17(6): 379–
385. 
Kolte AM, Steffensen R, Nielsen HS, Hviid TV, Christiansen OB. 2010. Study of the 
structure and impact of human leukocyte antigen (HLA)-G-A, HLA-G-B, and HLA-
G-DRB1 haplotypes in families with recurrent miscarriage. Hum Immunol 71(5): 
482–488. 
Korhonen J, Stenman UH, Ylostalo P. 1994. Serum human chorionic gonadotropin 
dynamics during spontaneous resolution of ectopic pregnancy. Fertil Steril 61(4): 
632–636. 
Kovalevskaya G, Birken S, Kakuma T, Ozaki N, Sauer M, Lindheim S, Cohen M, Kelly 
A, Schlatterer J, O’Connor JF. 2002. Differential expression of human chorionic 
gonadotropin (hCG) glycosylation isoforms in failing and continuing pregnancies: 
preliminary characterization of the hyperglycosylated hCG epitope. J Endocrinol 
172(3): 497–506. 
17
66 
Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. 2004. Evaluation of 
the association between hereditary thrombophilias and recurrent pregnancy loss: a 
meta-analysis. Arch Intern Med 164(5): 558–563. 
Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. 1990. A class I 
antigen, HLA-G, expressed in human trophoblasts. Science 248(4952): 220–223. 
Krieg SA, Fan X, Hong Y, Sang QX, Giaccia A, Westphal LM, Lathi RB, Krieg AJ, 
Nayak NR. 2012. Global alteration in gene expression profiles of deciduas from 
women with idiopathic recurrent pregnancy loss. Mol Human Reprod 18(9): 442–
450. 
Kubiczak M, Walkowiak GP, Nowak-Markwitz E, Jankowska A. 2013. Human 
Chorionic Gonadotropin Beta Subunit Genes CGB1 and CGB2 are Transcriptionally 
Active in Ovarian Cancer. International journal of molecular sciences 14(6): 
12650–12660. 
Kuningas M, Estrada K, Hsu YH, Nandakumar K, Uitterlinden AG, Lunetta KL, van 
Duijn CM, Karasik D, Hofman A, Murabito J et al. 2011. Large common deletions 
associate with mortality at old age. Hum Mol Genet 20(21): 4290–4296. 
Kusnierczyk P. 2013. Killer cell immunoglobulin-like receptor gene associations with 
autoimmune and allergic diseases, recurrent spontaneous abortion, and neoplasms. 
Front Immunol 4: 8. 
Laitinen T, Lokki ML, Tulppala M, Ylikorkala O, Koskimies S. 1991. Increased 
frequency of complement C4 ‘null’ alleles in recurrent spontaneous abortions. Hum 
Reprod 6(10): 1384–1387. 
Lapthorn AJ, Harris DC, Littlejohn A, Lustbader JW, Canfield RE, Machin KJ, Morgan 
FJ, Isaacs NW. 1994. Crystal structure of human chorionic gonadotropin. Nature 
369(6480): 455–461. 
Larsen EC, Christiansen OB, Kolte AM, Macklon N. 2013. New insights into 
mechanisms behind miscarriage. BMC medicine 11: 154. 
Le Marechal C, Masson E, Chen JM, Morel F, Ruszniewski P, Levy P, Ferec C. 2006. 
Hereditary pancreatitis caused by triplication of the trypsinogen locus. Nat Genet 
38(12): 1372–1374. 
Leach RE, Romero R, Kim YM, Chaiworapongsa T, Kilburn B, Das SK, Dey SK, 
Johnson A, Qureshi F, Jacques S et al. 2002. Pre-eclampsia and expression of 
heparin-binding EGF-like growth factor. Lancet 360(9341): 1215–1219. 
Ledig S, Ropke A, Wieacker P. 2010. Copy number variants in premature ovarian 
failure and ovarian dysgenesis. Sex Dev 4(4–5): 225–232. 
Lee AS, Gutierrez-Arcelus M, Perry GH, Vallender EJ, Johnson WE, Miller GM, 
Korbel JO, Lee C. 2008. Analysis of copy number variation in the rhesus macaque 
genome identifies candidate loci for evolutionary and human disease studies. Hum 
Mol Genet 17(8): 1127–1136. 
Lee CL, Chiu PC, Hautala L, Salo T, Yeung WS, Stenman UH, Koistinen H. 2013. 
Human chorionic gonadotropin and its free beta-subunit stimulate trophoblast 
invasion independent of LH/hCG receptor. Mol Cell Endocrinol 375(1–2): 43–52. 
Lee J, Oh J, Choi E, Park I, Han C, Kim do H, Choi BC, Kim JW, Cho C. 2007. 
Differentially expressed genes implicated in unexplained recurrent spontaneous 
abortion. Int J Biochem Cell Biol 39(12): 2265–2277. 
Lefranc MP, Hammarstrom L, Smith CI, Lefranc G. 1991. Gene deletions in the human 
immunoglobulin heavy chain constant region locus: molecular and immunological 
analysis. Immunodefic Rev 2(4): 265–281. 
67 
Lempiainen A, Hotakainen K, Blomqvist C, Alfthan H, Stenman UH. 2012. Hyper-
glycosylated human chorionic gonadotropin in serum of testicular cancer patients. 
Clin Chem 58(7): 1123–1129. 
Li M, Huang SJ. 2009. Innate immunity, coagulation and placenta-related adverse 
pregnancy outcomes. Thromb Res 124(6): 656–662. 
Li N, Stephens M. 2003. Modeling linkage disequilibrium and identifying recombi-
nation hotspots using single-nucleotide polymorphism data. Genetics 165(4): 2213–
2233. 
Li W, Zeng Chan W, Cui X, Xiao Feng L, Mao Sheng Y. 2010. Genome-wide 
screening for risk loci of idiopathic recurrent miscarriage in a Han Chinese 
population: a pilot study. Reprod Sci 17(6): 578–584. 
Lopata A, Hay DL. 1989. The potential of early human embryos to form blastocysts, 
hatch from their zona and secrete HCG in culture. Hum Reprod 4(8 Suppl): 87–94. 
Macklon NS, Geraedts JP, Fauser BC. 2002. Conception to ongoing pregnancy: the 
‘black box’ of early pregnancy loss. Hum Reprod Update 8(4): 333–343. 
Malhotra D, McCarthy S, Michaelson JJ, Vacic V, Burdick KE, Yoon S, Cichon S, 
Corvin A, Gary S, Gershon ES et al. 2011. High frequencies of de novo CNVs in 
bipolar disorder and schizophrenia. Neuron 72(6): 951–963. 
Mamtani M, Anaya JM, He W, Ahuja SK. 2010. Association of copy number variation 
in the FCGR3B gene with risk of autoimmune diseases. Genes Immun 11(2): 155–
160. 
Maston GA, Ruvolo M. 2002. Chorionic gonadotropin has a recent origin within pri-
mates and an evolutionary history of selection. Mol Biol Evol 19(3): 320–335. 
Matzuk MM, Krieger M, Corless CL, Boime I. 1987. Effects of preventing O-
glycosylation on the secretion of human chorionic gonadotropin in Chinese hamster 
ovary cells. Proc Natl Acad Sci U S A 84(18): 6354–6358. 
Matthiesen L, Kalkunte S, Sharma S. 2012. Multiple pregnancy failures: an immuno-
logical paradigm. Am J Reprod Immunol 67(4): 334–340. 
McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, Antin JH, 
Lee SJ, Ruutu T, Storer B et al. 2009. Donor-recipient mismatch for common gene 
deletion polymorphisms in graft-versus-host disease. Nat Genet 41(12): 1341–1344. 
McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, Shapero MH, 
de Bakker PI, Maller JB, Kirby A et al. 2008. Integrated detection and population-
genetic analysis of SNPs and copy number variation. Nat Genet 40(10): 1166–1174. 
McLellan AS, Zimmermann W, Moore T. 2005. Conservation of pregnancy-specific 
glycoprotein (PSG) N domains following independent expansions of the gene 
families in rodents and primates. BMC Evol Biol 5: 39. 
Miller-Lindholm AK, Bedows E, Bartels CF, Ramey J, Maclin V, Ruddon RW. 1999. A 
naturally occurring genetic variant in the human chorionic gonadotropin-beta gene 5 
is assembly inefficient. Endocrinology 140(8): 3496–3506. 
Miller-Lindholm AK, LaBenz CJ, Ramey J, Bedows E, Ruddon RW. 1997. Human 
chorionic gonadotropin-beta gene expression in first trimester placenta. 
Endocrinology 138(12): 5459–5465. 
Mills RE, Walter K, Stewart C, Handsaker RE, Chen K, Alkan C, Abyzov A, Yoon SC, 
Ye K, Cheetham RK et al. 2011. Mapping copy number variation by population-
scale genome sequencing. Nature 470(7332): 59–65. 
Mishra AK, Mahale SD, Iyer KS. 2003. Disulfide bonds Cys(9)-Cys(57), Cys(34)-
Cys(88) and Cys(38)–Cys(90) of the beta-subunit of human chorionic gonadotropin 
are crucial for heterodimer formation with the alpha-subunit: experimental evidence 
68 
for the conclusions from the crystal structure of hCG. Biochim Biophys Acta 
1645(1): 49–55. 
Moffett-King A. 2002. Natural killer cells and pregnancy. Nature reviews Immunology 
2(9): 656–663. 
Moghraby JS, Tamim H, Anacan V, Al Khalaf H, Moghraby SA. 2010. HLA sharing 
among couples appears unrelated to idiopathic recurrent fetal loss in Saudi Arabia. 
Hum Reprod 25(8): 1900–1905. 
Montgomery GW, Zondervan KT, Nyholt DR. 2013. The future for genetic studies in 
reproduction. Mol Human Reprod. 
Morgan FJ, Birken S, Canfield RE. 1975. The amino acid sequence of human chorionic 
gonadotropin. The alpha subunit and beta subunit. J Biol Chem 250(13): 5247–5258. 
Murray-Rust J, McDonald NQ, Blundell TL, Hosang M, Oefner C, Winkler F, 
Bradshaw RA. 1993. Topological similarities in TGF-beta 2, PDGF-BB and NGF 
define a superfamily of polypeptide growth factors. Structure 1(2): 153–159. 
Nagamani SC, Erez A, Ben-Zeev B, Frydman M, Winter S, Zeller R, El-Khechen D, 
Escobar L, Stankiewicz P, Patel A et al. 2013. Detection of copy-number variation 
in AUTS2 gene by targeted exonic array CGH in patients with developmental delay 
and autistic spectrum disorders. Europ J Hum Genet 21(3): 343–346. 
Nair RR, Khanna A, Singh K. 2013. Role of inflammatory proteins S100A8 and 
S100A9 in pathophysiology of recurrent early pregnancy loss. Placenta 34(9): 824–
827. 
Nelissen EC, van Montfoort AP, Dumoulin JC, Evers JL. 2011. Epigenetics and the 
placenta. Hum Reprod Update 17(3): 397–417. 
Norwitz ER, Schust DJ, Fisher SJ. 2001. Implantation and the survival of early 
pregnancy. New Engl J Med 345(19): 1400–1408. 
Novakovic B, Saffery R. 2012. The ever growing complexity of placental epigenetics – 
role in adverse pregnancy outcomes and fetal programming. Placenta 33(12): 959–
970. 
Ogasawara M, Aoki K, Okada S, Suzumori K. 2000. Embryonic karyotype of abortuses 
in relation to the number of previous miscarriages. Fertil Steril 73(2): 300–304. 
Pandey MK, Rani R, Agrawal S. 2005. An update in recurrent spontaneous abortion. 
Arch Gynecol Obstet 272(2): 95–108. 
Parrott AM, Sriram G, Liu Y, Mathews MB. 2011. Expression of type II chorionic 
gonadotropin genes supports a role in the male reproductive system. Mol Cell Biol 
31(2): 287–299. 
Pelak K, Need AC, Fellay J, Shianna KV, Feng S, Urban TJ, Ge D, De Luca A, 
Martinez-Picado J, Wolinsky SM et al. 2011. Copy number variation of KIR genes 
influences HIV-1 control. PLoS Biol 9(11): e1001208. 
Perry GH, Dominy NJ, Claw KG, Lee AS, Fiegler H, Redon R, Werner J, Villanea FA, 
Mountain JL, Misra R et al. 2007. Diet and the evolution of human amylase gene 
copy number variation. Nat Genet 39(10): 1256–1260. 
Philipp T, Philipp K, Reiner A, Beer F, Kalousek DK. 2003. Embryoscopic and 
cytogenetic analysis of 233 missed abortions: factors involved in the pathogenesis of 
developmental defects of early failed pregnancies. Hum Reprod 18(8): 1724–1732. 
Pierce JG, Parsons TF. 1981. Glycoprotein hormones: structure and function. Annu Rev 
Biochem 50: 465–495. 
Pinto D Pagnamenta AT Klei L Anney R Merico D Regan R Conroy J Magalhaes TR 
Correia C Abrahams BS et al. 2010. Functional impact of global rare copy number 
variation in autism spectrum disorders. Nature 466(7304): 368–372. 
69 
Potocki L, Chen KS, Park SS, Osterholm DE, Withers MA, Kimonis V, Summers AM, 
Meschino WS, Anyane-Yeboa K, Kashork CD et al. 2000. Molecular mechanism 
for duplication 17p11.2- the homologous recombination reciprocal of the Smith-
Magenis microdeletion. Nat Genet 24(1): 84–87. 
Rai R, Regan L. 2006. Recurrent miscarriage. Lancet 368(9535): 601–611. 
Rajcan-Separovic E, Diego-Alvarez D, Robinson WP, Tyson C, Qiao Y, Harvard C, 
Fawcett C, Kalousek D, Philipp T, Somerville MJ et al. 2010. Identification of copy 
number variants in miscarriages from couples with idiopathic recurrent pregnancy 
loss. Hum Reprod 25(11): 2913–2922. 
Red-Horse K, Zhou Y, Genbacev O, Prakobphol A, Foulk R, McMaster M, Fisher SJ. 
2004. Trophoblast differentiation during embryo implantation and formation of the 
maternal-fetal interface. J Clin Invest 114(6): 744–754. 
Redman CW, Sargent IL. 2010. Immunology of pre-eclampsia. Am J Reprod Immunol 
63(6): 534–543. 
Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero 
MH, Carson AR, Chen W et al. 2006. Global variation in copy number in the human 
genome. Nature 444(7118): 444–454. 
Reimand J, Arak T, Vilo J. 2011. g:Profiler – a web server for functional interpretation 
of gene lists (2011 update). Nucleic Acids Res 39(Web Server issue): W307–315. 
Revel A, Achache H, Stevens J, Smith Y, Reich R. 2011. MicroRNAs are associated 
with human embryo implantation defects. Hum Reprod 26(10): 2830–2840. 
Rey E, Kahn SR, David M, Shrier I. 2003. Thrombophilic disorders and fetal loss: a 
meta-analysis. Lancet 361(9361): 901–908. 
Rice P, Longden I, Bleasby A. 2000. EMBOSS: the European Molecular Biology Open 
Software Suite. Trends Genet 16(6): 276–277. 
Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker ID, Greaves 
M, Brenkel I, Regan L et al. 2006. Thrombophilia in pregnancy: a systematic 
review. Br J Haematol 132(2): 171–196. 
Roos S, Jansson N, Palmberg I, Saljo K, Powell TL, Jansson T. 2007. Mammalian 
target of rapamycin in the human placenta regulates leucine transport and is down-
regulated in restricted fetal growth. J Physiol 582(Pt 1): 449–459. 
Rull K, Hallast P, Uuskula L, Jackson J, Punab M, Salumets A, Campbell RK, Laan M. 
2008. Fine-scale quantification of HCG beta gene transcription in human 
trophoblastic and non-malignant non-trophoblastic tissues. Mol Hum Reprod 14(1): 
23–31. 
Rull K, Laan M. 2005. Expression of beta-subunit of HCG genes during normal and 
failed pregnancy. Hum Reprod 20(12): 3360–3368. 
Rull K, Nagirnaja L, Laan M. 2012. Genetics of recurrent miscarriage: challenges, 
current knowledge, future directions. Front Genet 3: 34. 
Rull K, Tomberg K, Koks S, Mannik J, Mols M, Sirotkina M, Varv S, Laan M. 2013. 
Increased placental expression and maternal serum levels of apoptosis-inducing 
TRAIL in recurrent miscarriage. Placenta 34(2): 141–148. 
Salker M, Teklenburg G, Molokhia M, Lavery S, Trew G, Aojanepong T, Mardon HJ, 
Lokugamage AU, Rai R, Landles C et al. 2010. Natural selection of human 
embryos: impaired decidualization of endometrium disables embryo-maternal 
interactions and causes recurrent pregnancy loss. PloS one 5(4): e10287. 
Schumacher A, Heinze K, Witte J, Poloski E, Linzke N, Woidacki K, Zenclussen AC. 
2013. Human chorionic gonadotropin as a central regulator of pregnancy immune 
tolerance. J Immunol 190(6): 2650–2658. 
18
70 
Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, 
Chen S, Feinberg T et al. 2009. GOLPH3 modulates mTOR signalling and ra-
pamycin sensitivity in cancer. Nature 459(7250): 1085–1090. 
Sedman L, Padhukasahasram B, Kelgo P, Laan M. 2008. Complex signatures of locus-
specific selective pressures and gene conversion on Human Growth Hormone/ 
Chorionic Somatomammotropin genes. Hum Mutat 29(10): 1181–1193. 
Shao W, Tang J, Song W, Wang C, Li Y, Wilson CM, Kaslow RA. 2007. CCL3L1 and 
CCL4L1: variable gene copy number in adolescents with and without human 
immunodeficiency virus type 1 (HIV-1) infection. Genes Immun 8(3): 224–231. 
Smith GR. 1988. Homologous recombination in procaryotes. Microbiol Rev 52(1): 1–
28. 
Stenman UH, Alfthan H, Hotakainen K. 2004. Human chorionic gonadotropin in 
cancer. Clin Biochem 37(7): 549–561. 
Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype 
reconstruction from population data. Am J Hum Genet 68(4): 978–989. 
Stirrat GM. 1990. Recurrent miscarriage. Lancet 336(8716): 673–675. 
Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird 
CP, de Grassi A, Lee C et al. 2007. Relative impact of nucleotide and copy number 
variation on gene expression phenotypes. Science 315(5813): 848–853. 
Stuart PE, Huffmeier U, Nair RP, Palla R, Tejasvi T, Schalkwijk J, Elder JT, Reis A, 
Armour JA. 2012. Association of beta-defensin copy number and psoriasis in three 
cohorts of European origin. J Invest Dermatol 132(10): 2407–2413. 
Zhang F, Gu W, Hurles ME, Lupski JR. 2009. Copy number variation in human health, 
disease, and evolution. Annu Rev Genomics Hum Genet 10: 451–481. 
Zhao L, Bracken MB, Dewan AT. 2013. Genome-Wide Association Study of Pre-
Eclampsia Detects Novel Maternal Single Nucleotide Polymorphisms and Copy-
Number Variants in Subsets of the Hyperglycemia and Adverse Pregnancy Outcome 
(HAPO) Study Cohort. Ann Hum Genet. 
Zhao L, Triche EW, Walsh KM, Bracken MB, Saftlas AF, Hoh J, Dewan AT. 2012. 
Genome-wide association study identifies a maternal copy-number deletion in 
PSG11 enriched among preeclampsia patients. BMC Pregnancy Childbirth 12: 61. 
Zimmermann G, Ackermann W, Alexander H. 2012. Expression and production of 
human chorionic gonadotropin (hCG) in the normal secretory endometrium: 
evidence of CGB7 and/or CGB6 beta hCG subunit gene expression. Biol Reprod 
86(3): 87. 
Zinaman MJ, Clegg ED, Brown CC, O’Connor J, Selevan SG. 1996. Estimates of 
human fertility and pregnancy loss. Fertil Steril 65(3): 503–509. 
Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Munstedt K, Rao CV, 
Lang U, Preissner KT. 2002. Characterization of human chorionic gonadotropin as a 
novel angiogenic factor. J Clin Endocrinol Metab 87(11): 5290–5296. 
Tam CW, Cheng AS, Ma RY, Yao KM, Shiu SY. 2006. Inhibition of prostate cancer 
cell growth by human secreted PDZ domain-containing protein 2, a potential 
autocrine prostate tumor suppressor. Endocrinology 147(11): 5023–5033. 
Teklenburg G, Salker M, Heijnen C, Macklon NS, Brosens JJ. 2010. The molecular 
basis of recurrent pregnancy loss: impaired natural embryo selection. Mol Human 
Reprod 16(12): 886–895. 
Tsampalas M, Gridelet V, Berndt S, Foidart JM, Geenen V, Perrier d’Hauterive S. 
2010. Human chorionic gonadotropin: a hormone with immunological and 
angiogenic properties. J Reprod Immunol 85(1): 93–98. 
71 
Uuskula L, Rull K, Nagirnaja L, Laan M. 2010. Methylation allelic polymorphism 
(MAP) in chorionic gonadotropin beta5 (CGB5) and its association with pregnancy 
success. J Clin Endocrinol Metab 96(1): E199–207. 
Vacic V, McCarthy S, Malhotra D, Murray F, Chou HH, Peoples A, Makarov V, Yoon 
S, Bhandari A, Corominas R et al. 2011. Duplications of the neuropeptide receptor 
gene VIPR2 confer significant risk for schizophrenia. Nature 471(7339): 499–503. 
Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord 
AS, Kusenda M, Malhotra D, Bhandari A et al. 2008. Rare structural variants disrupt 
multiple genes in neurodevelopmental pathways in schizophrenia. Science 
320(5875): 539–543. 
van Oppenraaij RH, Jauniaux E, Christiansen OB, Horcajadas JA, Farquharson RG, 
Exalto N. 2009. Predicting adverse obstetric outcome after early pregnancy events 
and complications: a review. Hum Reprod Update 15(4): 409–421. 
Wang JH, Chen XT, Wen ZS, Zheng M, Deng JM, Wang MZ, Lin HX, Chen K, Li J, 
Yun JP et al. 2012. High expression of GOLPH3 in esophageal squamous cell 
carcinoma correlates with poor prognosis. PloS one 7(10): e45622. 
Wang X, Jiang W, Zhang D. 2013. Association of 14-bp insertion/deletion poly-
morphism of HLA-G gene with unexplained recurrent spontaneous abortion: a meta-
analysis. Tissue Antigens 81(2): 108–115. 
Vatin M, Burgio G, Renault G, Laissue P, Firlej V, Mondon F, Montagutelli X, Vaiman 
D, Serres C, Ziyyat A. 2012. Refined mapping of a quantitative trait locus on 
chromosome 1 responsible for mouse embryonic death. PloS one 7(8): e43356. 
Watson CT, Steinberg KM, Huddleston J, Warren RL, Malig M, Schein J, Willsey AJ, 
Joy JB, Scott JK, Graves TA et al. 2013. Complete haplotype sequence of the human 
immunoglobulin heavy-chain variable, diversity, and joining genes and 
characterization of allelic and copy-number variation. Am J Hum Genet 92(4): 530–
546. 
Wheeler E, Huang N, Bochukova EG, Keogh JM, Lindsay S, Garg S, Henning E, 
Blackburn H, Loos RJ, Wareham NJ et al. 2013. Genome-wide SNP and CNV 
analysis identifies common and low-frequency variants associated with severe early-
onset obesity. Nat Genet 45(5): 513–517. 
Wilcox AJ, Baird DD, Weinberg CR. 1999. Time of implantation of the conceptus and 
loss of pregnancy. New Engl J Med 340(23): 1796–1799. 
Wilcox AJ, Weinberg CR, O’Connor JF, Baird DD, Schlatterer JP, Canfield RE, 
Armstrong EG, Nisula BC. 1988. Incidence of early loss of pregnancy. New Engl J 
Med 319(4): 189–194. 
Wilczynski JR. 2006. Immunological analogy between allograft rejection, recurrent 
abortion and pre-eclampsia – the same basic mechanism? Hum Immunol 67(7): 492–
511. 
Witt CS, Goodridge J, Gerbase-Delima MG, Daher S, Christiansen FT. 2004. Maternal 
KIR repertoire is not associated with recurrent spontaneous abortion. Hum Reprod 
19(11): 2653–2657. 
von Salome J, Gyllensten U, Bergstrom TF. 2007. Full-length sequence analysis of the 
HLA-DRB1 locus suggests a recent origin of alleles. Immunogenetics 59(4): 261–
271. 
Wood CS, Hung CS, Huoh YS, Mousley CJ, Stefan CJ, Bankaitis V, Ferguson KM, 
Burd CG. 2012. Local control of phosphatidylinositol 4-phosphate signaling in the 
Golgi apparatus by Vps74 and Sac1 phosphoinositide phosphatase. Mol Biol Cell 
23(13): 2527–2536. 
72 
Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E, Sabatti C, Geurts van 
Kessel A, Brunner HG, Ophoff RA, Veltman JA. 2008. Recurrent CNVs disrupt 
three candidate genes in schizophrenia patients. Am J Hum Genet 83(4): 504–510. 
Xue WC, Chan KY, Feng HC, Chiu PM, Ngan HY, Tsao SW, Cheung AN. 2004. 
Promoter hypermethylation of multiple genes in hydatidiform mole and 
choriocarcinoma. The Journal of molecular diagnostics: JMD 6(4): 326–334. 
Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B, Hebert M, Jones KN, 
Shu Y, Kitzmiller K et al. 2007. Gene copy-number variation and associated 
polymorphisms of complement component C4 in human systemic lupus erythe-
matosus (SLE): low copy number is a risk factor for and high copy number is a 
protective factor against SLE susceptibility in European Americans. Am J Hum 
Genet 80(6): 1037–1054. 
Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. 2006. Roles for 
HLA and KIR polymorphisms in natural killer cell repertoire selection and 
modulation of effector function. J Exp Med 203(3): 633–645. 
Yuen RK, Avila L, Penaherrera MS, von Dadelszen P, Lefebvre L, Kobor MS, 
Robinson WP. 2009. Human placental-specific epipolymorphism and its association 
with adverse pregnancy outcomes. PloS one 4(10): e7389. 
  
73 
SUMMARY IN ESTONIAN 
Korduva raseduse katkemise genoomsed ja  
geneetilised riskitegurid 
Raseduse katkemine ehk spontaanabort on kõige sagedasem rasedustüsistus 
ning kuni 15% kliinilisest diagnoositud rasedustest katkevad iseeneslikult. Ligi 
3%-l viljakas eas paaridel leiab spontaanabort aset järjestikku kolm või enam 
korda, mille puhul diagnoositakse korduv raseduse katkemine (KRK). Järgne-
vate raseduste korral on KRK patsientidel suurenenud risk nii uue raseduse 
katkemiseks kui ka enneaegse sünnituse esinemiseks. KRK näol on tegemist 
heterogeense haigusega, mille teadaolevate riskitegurite spekter on lai, kuid 
umbes pooltel haigusjuhtudel ei ole tekkepõhjus endiselt määratletav. Selge 
põhjuseta ehk idiopaatilist KRK esinemise risk on patisentide lähi-sugulastel 
kaks korda kõrgem kui mitte-suguluses olevatel indiviididel viidates pärilikkuse 
kompnendile KRK patogeneesis. Idiopaatilise KRK geneetiliste riskide kaar-
distamiseks on tänaseks läbi viidud hulgaliselt uuringuid rohkem kui saja 
kandidaat-geeni põhjal, mille funktsioon varajase raseduses on teada. Sellele 
vaatamata ei ole siiani tuvastatud ühtegi sagedast geneetilist markerit, mis oleks 
spetsiifline KRK-le ning mis oleks rakendatav kliinilises diagnostikas ja ravis. 
Kaasaegsed kogu genoomi, transkriptoomi ja/või proteoomi-põhised metoodi-
kad võimaldavad aga kompleksset lähenemist KRK pärilikkuskomponendi 
analüüsil ning tuvastada uusi geene ja mehhanisme, mis potentisaalselt mõju-
tavad varajase raseduse kulgu. 
Inimese koorioni gonadotropiini (human chorionic gonadotropin, hCG), 
mida kutsutakse ka ‘raseduse hormooniks’, toodab blastotsüst juba 8-rakulises 
staadiumis ning selle olemasolu on embrüo pesastumiseks ja raseduse säili-
miseks kriitilise tähtsusega. Heterodimeerse hCG spetsiifilisuse määrab  
β-alaühik, mille normist kõgem või madalam avaldumine on tuvastatud nii 
emakavälise raseduse, moolraseduse kui ka idiopaatilise KRK puhul. Seega on 
β-alaühikut kodeerivad geenid ja neis esinev geneetiline varieeruvus huvi-
pakkuv kui potentsiaalne KRK riskitegur. hCGβ alaühikut kodeerivad neli 
duplikaat-geeni (CGB, CGB7 ning kõige kõrgema avaldumisega CGB5 ja 
CGB8), mis asuvad ühises geeniklastris 19. kromosoomil koos lutropiini  
β-alaühikut tootva (LHB) ja kahe hCGβ alaühikut mitte-kodeeriva (CGB1 ja 
CGB2) geeniga. Siiani ei ole teostatud põhjalikke hCGβ geenide varieeruvuse 
uuringuid KRK kontekstis valdavalt metoodiliste takistuste tõttu, mis lähtuvad 
LHB/CGB geeniklastri keerulisest struktuurist, suurest DNA kordusjärjestuste 
arvust ning CGB geenide sarnasusest nii DNA (97–99%) kui valgu (98–100%) 
tasemel. 
DNA koopiaarvu varieeruvus (copy number variants, CNV), mis hõlmab 
DNA struktuurseid ümberkorraldusi suurusega üle 50 aluspaari, on laiaulatuslik 
fenomen mõjutades kuni 30% inimese kogu genoomi järjestusest. Üksikuid 
CNV piirkondasid kui ka CNV-de summarset rikastatust inimese genoomis on 
19
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seostatud mitmete haiguste patogeneesiga nagu näiteks autism, skisofreenia, 
ülekaalulisus ja pikaealisus. Inimese reproduktiivhaiguste kontekstis on  
CNV-sid vähe uuritud ning idiopaatilise KRK puhul on CNV-de profiili ana-
lüüsi varasemalt teostatud ainult 24 aborteerunud platsenta proovis. Suure-
mahulise platsenta-põhise CNV-de analüüsi limiteerivaks faktoriks KRK puhul, 
mis leiab aset varajase raseduse käiugus, on aga kvaliteetse bioloogilise mater-
jali raskendatud kättesaadavus. Kuna loote genoomi panustavad ema ja isa 
võrdselt, siis on alternatiivina võimalik hinnata vanemate geneetilist eelsoodu-
must KRK esinemiseks verest eraldatud DNA põhjal. 
 
Käesoleva doktoritöö kirjanduse ülevaates on koondatud info tänaseks teada-
olevatest idiopaatilise KRK riskiteguritest ning geneetilistest assotsiatsiooni-
uuringutest, mis on teostatud nii kogu genoomi kui ka üksikute markerite 
tasemel. Lisaks on kirjeldatud hCG hormooni, hCGβ alaühikut, CGB geenide 
funktsionaalseid ja struktuurseid omadusi ning ühtlasi CNV-de rolli nii 
kompleks-haiguste kui ka rasedustüsistuste kujunemisel. 
 
Doktoritöö eksperimentaalses osas on püstitatud järgmised eesmärgid: 
 
I. LHB/CGB geeniklastri kaardistamine ning detailne DNA järjestuse analüüs 
eesmärgiga tuvastada tegureid, mis mõjutavad piirkonna struktuurset ja 
evolutsioonilist dünaamikat  
II. DNA ühenukleotiidsed variandid kõige rohkem hCG β-alaühikut tootvates 
geenides CGB5 ja CGB8 ning nende seos KRK esinemisega: 
 DNA ühenukleotiidsete variantide tuvastamine CGB5 ja CGB8 
geenides ning juht-kontrolluuringu teostamine Eesti, Soome ja Taani 
valimites 
 CGB5 ja CGB8 geenides esinevate mitte-sünonüümsete mutatsioonide 
struktuurne ja funktsionaalne analüüs in vitro 
III. DNA koopiaarvu varieeruvus (CNV) kui uus KRK geneetiline marker: 
 CNV-de genoomse profiili analüüs ning CNV-de poolt häiritud bio-
loogiliste radade tuvastamine 
 Uute CNV piirkondade identifitseerimine, mis suurendavad KRK kuju-
nemise riski 
 
Uurimistöö peamised tulemused on järgmised: 
 
Ühenukleotiidete geneetilise markerite roll KRK esinemisel LHB/CGB geeni-
klastri näitel 
 
1.  LHB/CGB geeniklaster, mis koosneb ühest LHB ja kuuest CGB geeni-
koopiast inimesel, on kujunenud korduvate DNA ümberkorralduste taga-
järjel, mida on tõenäoliselt soodustanud aktiivsed rekombinatsiooni alad piir-
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konnas. LHB/CGB geenide varieeruvust on mõjutanud ühelt poolt geeni-
konversioon, mis levitab polümorfisme geenikoopiate vahel, ning teisalt 
funktsionaalsed piirangud, mis garanteerivad hCGβ geenide aktiivse aval-
dumise. Arvestades genoomse piirkonna dünaamikat võib eeldada, et 
LHB/CGB geeniklaster on ka käesolevalt struktuuri ja varieeruvuse poolest 
ebastabiilne. 
2.  Kõige rohkem hCGβ-t tootvatele geenidele CGB5 ja CGB8 on iseloomulik 
riskivariantide puudumine Eesti, Soome ja Taani KRK-ga patsientidel. 
CGB5 promootor-alas esineb neljast polümorfismist koosnev motiiv, mis 
omab protektiivset efekti KRK esinemise suhtes ning mis on üle kandunud 
vastavast CGB8 promootori piirkonnast geenikonversiooni teel. CGB8 on 
omakorda kõige efektiivsem hCG β-alaühikut produtseeriv geenikoopia ning 
selle promootor-ala on balansseeriva valiku all. 
3.  Kolme mitte-sünonüümse CGB5 ja CGB8 geenis asuva mutatsiooni struk-
tuurne ja funktsionaalne uuring tuvastas häirunud hCG hormooni assamb-
leerumise p.Val56Leu aminohappe asenduse puhul (tekib 10% metsik-tüüpi 
hCG-st). Samas põhjustab p.Val56Leu asendus hormooni suuremat bio-
aktiivsust LH/CG retseptoriga seondumisel seega täielikult või osaliselt 
kompenseerides vähenenud hCG kogust. Kuna analüüsitud mutatsioonide 
puhul ei ole uuritud indiviidide seas tuvastatud homosügootseid kandjaid 
ning tõenäoliselt tolereeritakse CGB5 ja CGB8 geenides ainult „kerge” 
funktsionaalse mõjuga aminohappe muutusi, siis võib eeldada, et antud 
geenide hoidmine funktsionaalselt aktiivsetena on oluline edukaks raseduse 
kulgemiseks. 
 
 
Globaalsete geneetiliste markerite roll KRK esinemisel CNV-de genoomse 
profiili näitel 
1.  CNV-de genoomne kaardistamine tuvastas, et KRK patisentidel on CNV-de 
summaarne ulatus ja pikkade (>100 kb) geenirikaste deletsioonide osakaal 
genoomi kohta suurem kui viljakatel kontrollidel. Ulatuslik CNV-de 
esinemine genoomis suurendab tõenäosust, et ümberkorraldused hõlmavad 
geene, mis on olulised varajases raseduse etapis. 
2.  KRK patsientidel esinevate CNV-de poolt ümberkorraldatud geenide funkt-
sionaalse rikastatuse analüüsil ilmnes, et struktuursed ümberkorraldused 
mõjutavad kõige enam bioloogilisi radasid, mis on seotud immuunvastuse 
väljakujunemisega platsentas. Tulemused kinnitavad, et emapoolse balans-
seeritud immuntolerantsuse tekkel loote poolt esitletud isa antigeenidele on 
määrava tähstusega roll edukaks raseduse kulgemiseks. 
3.  Enamlevinud CNV piirkondade-põhine uuring Eesti ja Taani valimites 
tuvastas uue geneetilise markeri, mille esinemisega kaasneb suurem KRK 
risk naispartneritel. Mitme koopiana esinev duplikatsioon 5p13.3 kromo-
somaalses piirkonnas hõlmab kahte geeni PDZD2 ja GOLPH3, mis on kõige 
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aktiivsemalt avaldunud platsentas ning mida pole varasemalt seostatud 
varajase rasedusega.  
 
Vaatamata laialdastele uuringutele KRK geneetiliste põhjuste selgitamiseks, ei 
ole siiani tuvastatud haiguse-spetsiifilisi markereid. Raseduse katkemise riski 
oluliselt mõjutavate geenide puhul, nagu seda on hCGβ duplikaat-geenid, on 
ilmselt põhjuseks loote elujõulisust oluliselt häirivate geneetiliste variandite 
evolutsioon negatiivse valiku surve all. Üha kasvava andmestiku põhjal on 
pakutud, et üksikute suure efektiga mutatsioonide ja polümorfsete markerite 
asemel võivad KRK kujunemist mõjutada väikese efektiga geneetiliste 
variantide kombinatsioonid või esineb igal KRK perekonnal oma unikaalne 
riskitegur. 
DNA koopiaarvu varieeruvuse analüüs kogu genoomi tasemel on võimal-
danud hüpoteesi-vaba lähenemist ja uute KRK-seoseliste lookuste tuvastamist 
ning on kinnitanud DNA struktuursete ümberkorralduste rolli varajase raseduse 
katkemisel. Ühtlasi rõhutavad käesoleva doktoritöö raames esitatud tulemused 
KRK geneetilise etioloogia heterogeensust. 
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